The full 2026 ASCO exhibitor directory — 429 companies. Filter by product category, cancer type, or status.
AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas–immunology, oncology, neuroscience, and eye care– and the products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X (formerly Twitter), and YouTube.
Adaptive Biotechnologies is a commercial-stage biotech company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. Adaptive’s goal is to develop and commercialize immune-driven diagnostics and therapeutics tailored to each individual patient.
Agilent Technologies Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.83 billion in fiscal 2023 and employs approximately 18,000 people worldwide. Information about Agilent is available at www.agilent.com.
Almac Diagnostic Services is a precision medicine company specialising in biomarker driven clinical trials. Our global CLIA and CAP accredited laboratories cover UK, Europe, USA and APAC regions. Our core services include: • Multi-Omic Services • Clinical Biomarker & CDx Development • Clinical Testing Make the winning move today www.almacgroup.com/diagnostics
The American Association for Cancer Research is a dynamic and vibrant organization that offers its members opportunities to participate more fully in the global effort to prevent and cure all cancers.
Amgen harnesses the best of biology and technology to fight the world’s toughest diseases, and make people’s lives easier, fuller and longer. We helped establish the biotechnology industry, and we remain on the cutting-edge of innovation, using technology and human genetic data to push beyond what’s known today.
The ASCO Booth is your hub to find your place in our global community and discover how you can get involved with ASCO. • Get Involved: Meet our Membership Team to join, renew, or explore volunteer opportunities. • Network: Connect with colleagues from 170+ countries in a collaborative space designed to foster connection. • Recharge: Take a well-deserved "paws" with the comfort dogs or capture a memory at our photo op wall.
Staff from participating societies are exhibiting at the State Oncology Societies Booth to represent their organizations, interact with attendees, and discuss the importance of local-level involvement in issues affecting oncology professionals. Attendees are encouraged to visit the booth to network and receive information about the work occurring in their specific state or region. ASCO staff will also be available to represent those Affiliates unable to send a representative. Alabama Cancer Congress Denali Oncology Group The Arizona Clinical Oncology Society Arkansas Association of Cancer Professionals Association of Northern California Oncologists Medical Oncology Association of Southern California Rocky Mountain Oncology Society Dakota Oncology Society Florida Society of Clinical Oncology Hawaii Society of Clinical Oncology Indiana Oncology Society Iowa Oncology Society Kansas Society of Clinical Oncology Kentucky Society of Clinical Oncology Louisiana Oncology Society Michigan Society of Hematology and Oncology Minnesota Society of Clinical Oncology Missouri Oncology Society Montana State Oncology Society Nevada Oncology Society New Mexico Society of Clinical Oncology Empire State Hematology & Oncology Society North Carolina Oncology Association Ohio Hematology Oncology Society Pennsylvania Society of Oncology and Hematology South Carolina Oncology Society Tennessee Oncology Practice Society Texas Society of Clinical Oncology Washington State Medical Oncology Society West Virginia Oncology Society Wisconsin Association of Hematology and Oncology Wyoming State Oncology Society
The ASCO-Sponsored Patient Advocacy Booth is designed to give not-for-profit patient advocacy organizations an opportunity to promote their services, programs, and resources to the professional oncology community. This booth provides a venue where participants can display materials and where meeting attendees and patient advocates can network and exchange information. Exhibiting organizations include: List of Exhibitors: Accessia Health Alliance for Fertility Preservation American Brain Tumor Association American Lung Cancer Screening Initiative Bladder Cancer Advocacy Network Cancer and Careers Cancer Support Community CANCER101 CancerCare Cholangiocarcinoma Foundation Colorectal Cancer Alliance Dear Jack Foundation Debbie's Dream Foundation: Curing Stomach Cancer End Brain Cancer Initiative End Lung Cancer Now Fight Colorectal Cancer Firefighter Cancer Support Network Gastric Cancer Foundation Global Resource for Advancing Cancer Education Head for the Cure Foundation Health, Hope & Hip-Hop Foundation HealthTree Foundation HPV Cancers Alliance Imerman Angels One-On-One Cancer Support International Brain Tumour Alliance (IBTA) Irish Cancer Society Kidney Cancer Association Kits to Heart Lung Cancer Research Foundation LUNGevity Foundation Man Up To Cancer Mesothelioma Applied Research Foundation MIB Agents Osteosarcoma Alliance My Density Matters National Blood Clot Alliance National Brain Tumor Society National Organization for Rare Disorders (NORD) Pancreatic Cancer Action Network (PanCAN) Patient Empowerment Network Project PINK BLUE Rare Cancer Research Foundation Support For People With Oral And Head And Neck Cancer (SPOHNC) Susan G. Komen ® The Desmoid Project The Dorcas Cancer Foundation (TDCF) ThyCa: Thyroid Cancer Survivors' Association, Inc. Triage Cancer VHL Alliance Wonders & Worries Young Adult Survivors United
Astellas is committed to turning science into medical solutions that bring value and hope to patients and their families. Keeping our focus on addressing unmet medical needs and conducting our business with ethics and integrity enables us to improve the health of people throughout the U.S. and around the world.
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Please visit astrazeneca-us.com for more information.
AVEO Oncology (“AVEO”) is an oncology-focused biopharmaceutical company committed to providing innovative solutions to improve cancer patients’ lives. On January 19, 2023, AVEO was acquired by LG Chem, Ltd. (“LG Chem”), establishing a U.S. commercial presence for LG Chem and expanding LG Chem’s global oncology portfolio. AVEO continues to commercialize FOTIVDA® (tivozanib) in the U.S. To learn more about FOTIVDA efficacy, safety, and relevant resources, visit FOTIVDAHCP.com.
Headquartered in Menlo Park, California, Northstar by BillionToOne is a next-generation molecular diagnostics company advancing precision oncology through highly sensitive, accessible testing. Its proprietary single-molecule NGS platform, powered by Quantitative Counting Templates™ (QCT™), enables precise DNA molecule counting. Northstar’s portfolio includes Northstar Select® for therapy selection and Northstar Response® for real-time treatment monitoring, offering a more complete view of the cancer journey.
BioNTech is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. We exploit a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Our diversified oncology portfolio of product candidates includes individualized and off-the-shelf mRNA cancer vaccines, targeted therapies comprising chimeric antigen receptor T cells and antibody-drug conjugates, and novel immunomodulators.
Blueprint Medicines is a global precision therapy company that invents life-changing medicines. Applying an approach that is both precise and agile, we create therapies that selectively target the root cause of disease, with the goal of staying one step ahead across stages of disease. Since 2011, we have leveraged our research platform, including expertise in molecular targeting and world-class drug design capabilities, to rapidly and reproducibly translate science into a broad pipeline of precision therapies. Today, we have brought our approved medicines to patients in the US.
BostonGene is redefining cancer patient care and drug development through the integration of omnimodal data and AI. Built and validated through an extensive real-world clinical testing network, BostonGene's foundation model for tumor and immune biology integrates genomic, transcriptomic, and immune data with clinical outcomes to generate biologically grounded, actionable insights. These insights enable biopharma partners design and de-risk trials, identify novel targets, and optimize therapeutic response prediction while improving patient care through clinically integrated innovation.
Brand Institute (BI) is the global leader in pharmaceutical branding and name development, offering end-to-end services spanning brand strategy, name creation, trademark searches, regulatory support, and visual identity. Its wholly-owned subsidiary, Drug Safety Institute (DSI), whose leadership includes former officials from the FDA, EMA, Health Canada, AMA, and WHO, provides expert regulatory guidance to clients worldwide. For 20 consecutive years, BI has partnered on over 75% of new drug name approvals globally with oncology representing the largest segment of BI’s portfolio.
Bristol Myers Squibb is a leading global biopharma company focused on discovering, developing and delivering innovative medicines for patients with serious diseases in areas including oncology, hematology, immunology, cardiovascular and neuroscience. Our employees work every day to transform patients’ lives through science.
Cancer Communications is an open access, peer-reviewed online journal published in association with Sun Yat-sen University Cancer Center, covering basic, clinical, and translational cancer research, including clinical trials, epidemiology, molecular and cellular biology, and genetics.
Caris Life Sciences® is a leading patient-centric, next-generation AI TechBio company and precision medicine pioneer actively developing and delivering innovative solutions to revolutionize healthcare. Through comprehensive molecular profiling (DNA, RNA and proteins), the application of AI and machine learning algorithms, Caris has created the large-scale, multi-modal database and computing capability needed to analyze and unravel the molecular complexity of disease. CarisLifeSciences.com.
Celcuity is a clinical-stage biotechnology company developing targeted therapies for the treatment of multiple solid tumor indications. The company's lead therapeutic candidate is gedatolisib, a potent, pan-PI3K and mTORC1/2 inhibitor that comprehensively blockades the PI3K/AKT/mTOR pathway. Gedatolisib is currently being evaluated in Phase 3 trials as a combination therapy in patients with HR+/HER2- advanced breast cancer and a Phase 1/2 clinical trial in patients with metastatic castration resistant prostate cancer.
ConcertAI is the leader in Real-World Evidence (RWE) and AI technology solutions for life sciences and health care. Our mission is to accelerate insights and outcomes for patients through leading real-world data, AI technologies, and scientific expertise in partnership with the leading biomedical innovators, health care providers, and medical societies. For more information, visit us at www.concertai.com
With more than 120 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 16,000 employees around the world draw upon a rich legacy of innovation to realize our 2030 Vision to become an Innovative Global Healthcare Company Contributing to the Sustainable Development of Society.
Day One is a biopharmaceutical company founded to address a critical unmet need - therapeutic development in pediatric cancers. Day One is committed to developing targeted therapies for patients with life-threatening diseases and redefine what’s possible for all people living with cancer, regardless of age, starting from Day One.
Deciphera is a member company of the Ono Pharma group of Japan. We are a commercial-stage company on a mission to develop and deliver transformational medicines to patients. Headquartered in Waltham, MA with research facilities in Lawrence, KS, Deciphera is leading Ono Pharmaceutical’s expansion in the U.S. and Europe with a robust pipeline of clinical programs with first- or best-in-class potential. Our areas of focus include oncology, immunology & inflammation, and neurology.
Dendreon is a commercial-stage biopharmaceutical company and end-to-end provider of manufacturing services for the cell therapy market. Dendreon was founded on the belief that immunotherapy made from a patient’s own cells will transform disease treatment. Our product PROVENGE® (sipuleucel-T) was the first FDA-approved immunotherapy to harness the innate benefits of personalized cellular treatment made from a patient’s own immune cells. Now Dendreon is helping to advance other cell therapies from clinic to market by leveraging its development and commercialization experience.
Einstein Hospital Israelita, ranked 16th by Newsweek’s World’s Best Hospitals and number one in Latin America, operates at every stage of healthcare in Brazil, in both the private and public systems, and in teaching, research, innovation and social responsibility. Recognized as the 17th best hospital in the world for oncology, Einstein is set to open its Center for Advanced Care and Therapies in Oncology and Hematology in 2027. It will provide a dedicated space for specialized research and care, with a focus on personalized healthcare, innovation, big data, cell therapy & technology
At Eisai, everything we do is guided by a simple principle: patients and their families come first. We call this human health care or hhc, and this mission is the spark that ignites us to discover innovative solutions and therapies that help address unmet needs within the metastatic and marginalized communities that we seek to serve. We won't stop pursuing breakthroughs until the world is cancer-free, because we never lose sight of who we’re fighting for. Science-Driven. Human-Centric. That’s Eisai Oncology. For more information, please visit us.eisai.com.
Elevar Therapeutics is a fully integrated biopharmaceutical company built on the promise of elevating treatment experiences and outcomes for patients who have limited or inadequate therapeutic options. Our experience is rooted in oncology, and we apply the same rigor and diligence that comes with this knowledge to identifying and developing promising medicines for complex yet under-treated health conditions across a range of therapeutic areas.
EMD Serono, Inc. and SpringWorks Therapeutics, Inc. are both healthcare companies of Merck KGaA, Darmstadt, Germany. From aspiring to help more patients become cancer survivors to reimagining what it means to live with a rare tumor, together we focus on advancing specialty innovation—helping to create, improve, and prolong lives, As One for Patients.
Founded in 1997, Ergomed is a global full-service Phase I–IV clinical development partner with deep expertise in oncology, including rare cancers and advanced therapies. We combine scientific depth, operational excellence, and the agility of a mid-sized CRO to support complex international oncology studies. With experience across 500+ oncology trials and 30,000+ oncology patients, Ergomed helps sponsors accelerate development through tailored clinical, regulatory, and patient support solutions from early development through post-marketing.
EVERSANA® is the leading provider of global commercial services to the life sciences industry. Our integrated solutions are rooted in the patient experience and span all stages of the product life cycle to deliver long-term, sustainable value for patients, prescribers, channel partners and payers. We serve more than 500 organizations, including innovative start-ups and established pharmaceutical companies to advance life science solutions for a healthier world. To learn more about EVERSANA, visit eversana.com.
A leading provider of cancer screening and diagnostic tests, Exact Sciences gives patients and health care professionals the clarity needed to take life-changing action earlier. Building on the success of the Cologuard® and Oncotype® tests, Exact Sciences is investing in its pipeline to develop innovative solutions for use before, during, and after a cancer diagnosis. For more information, visit ExactSciences.com, follow Exact Sciences on X (formerly known as Twitter) @ExactSciences, or find Exact Sciences on LinkedIn and Facebook.
Exelixis is a globally ambitious oncology company innovating next-generation medicines and regimens at the forefront of cancer care. Powered by drug discovery and development excellence, we are rapidly evolving our product portfolio to target an expanding range of tumor types and indications – harnessing decades of robust investment in our science and partnerships – to advance our investigational programs and extend the impact of our flagship commercial product. Exelixis is driven by a bold scientific pursuit to create transformational treatments that give more patients hope for the future.
Formedics is a healthcare media and engagement company built around physician communities. We create platforms where clinicians connect, collaborate, and learn through peer-led content, social discussion, live events, and point-of-care experiences embedded in the clinical workflow. Our programs help pharmaceutical and life science companies engage clinicians in trusted, meaningful ways while empowering physicians to share knowledge and shape the future of medicine.
Foundation Medicine is a pioneer in molecular profiling for cancer, working to shape the future of clinical care and research. We collaborate with a broad range of partners across the cancer community and strive to set the standard for quality, scientific excellence, and regulatory leadership. Our deep understanding of cancer biology helps physicians make informed treatment decisions for their patients and empowers researchers to develop new medicines. We are driven to help our partners find answers and take action as we work to transform cancer care.
GE HealthCare is a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, dedicated to providing integrated solutions, services, and data analytics to make hospitals more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, connected, and compassionate care, while simplifying the patient’s journey across the care pathway.
Genmab is an international biotechnology company dedicated to improving the lives of people with cancer and other serious diseases through innovative antibody medicines. Genmab is recognized for its expertise in antibody science. The company continues to advance its late-stage pipeline, including wholly owned programs, with the goal of delivering transformative medicines to patients. Visit Genmab.com, LinkedIn and X.
GRAIL stands at the forefront of cancer screening innovation. Leveraging next-generation DNA sequencing, population-scale clinical studies, and state-of-the-art machine learning to help detect multiple cancer types. Visit Galleri.com to learn about the Galleri® multi-cancer early detection test.
Oncology is an emerging therapeutic area for GSK where we are committed to maximising patient survival with a current focus on haematologic malignancies, gynaecologic cancers, and other solid tumours through breakthroughs in immuno-oncology and tumour-cell targeting therapies.
Helsinn is a global pharmaceutical company that has been operating for more than 45 years. Founded on broad technical expertise, we build, launch, and commercialize solid brands with a strong focus on oncology and supportive care. We reach patients worldwide through a unique and diverse commercial and supply network, complemented by direct sales in the US. Committed to enhancing quality of life, we embrace sustainable growth as a core aspect of our strategic vision.
For more than 25 years, Aixial Group has partnered with biotech companies to advance complex oncology clinical programs. Acting as a true strategic partner, we align operational execution with scientific, regulatory, and business objectives. With experience across 300+ oncology studies at 7,400 global sites, we specialize in complex trial designs including adaptive, umbrella, dose-optimization, and combination therapies. Our expert team with rigorous oversight ensures proactive partnership, efficient execution, risk mitigation, and timely delivery of innovative oncology therapies worldwide.
Imaging Endpoints (IE) is the largest oncology focused imaging CRO globally and is widely recognized for conducting the industry’s largest, most complex, and most successful imaging trials for both solid and liquid tumor indications. IE is based in Scottsdale, Arizona with offices around the word including Cambridge, Massachusetts; London, United Kingdom; Basel, Switzerland; Leiden, Netherlands; Hyderabad, India; and Shanghai, China
ImmunityBio, Inc. develops next-generation cancer therapies and vaccines that complement and amplify the immune system. Our broad, proprietary immunotherapy, NK cell therapy, and vaccine platforms are designed to attack cancer by activating both the innate and adaptive immune system in an orchestrated manner to outsmart the disease and establish “immunological memory” that confers long-term benefit for the patient.
Immunocore is a commercial-stage biotechnology company that discovered, developed and commercialized the world’s first approved T cell receptor (TCR) therapy. Our mission is to radically improve outcomes for patients with cancer, infectious diseases, and autoimmune diseases, by pioneering and delivering transformative immunomodulating medicines. Built on our proprietary ImmTAX technology, we have a pipeline of investigational bispecific TCR therapies across a broad range of diseases, including multiple types of cancers, HIV, type 1 diabetes, and other autoimmune diseases.
Inizio is a trusted, strategic commercialization partner for health and life sciences organizations. Oncology is our largest therapeutic area, with experience across more than 190 oncology assets in the past two years and support for over 50% of recent product launches. We partner across the full clinical development and commercialization journey to help clients simplify complexity, unlock value, and deliver meaningful impact for patients.
The International Society of Liquid Biopsy (ISLB) is the first international professional organization committed to the improvement and implementation of liquid biopsies in clinical routine practice and the promotion of a multidisciplinary approach for the diagnosis and treatment of cancer patients based on the use of liquid biopsies.
Iovance Biotherapeutics, Inc. aims to be the global leader in innovating, developing, and delivering tumor infiltrating lymphocyte (TIL) therapies for patients with cancer. We are pioneering a transformational approach to cure cancer by harnessing the human immune system’s ability to recognize and destroy diverse cancer cells in each patient. The Iovance TIL platform has demonstrated promising clinical data across multiple solid tumors. We are committed to continuous innovation in cell therapy, including gene-edited cell therapy, that may extend and improve life for patients with cancer.
Ipsen is a global biopharmaceutical company with a focus on bringing transformative medicines to patients in three therapeutic areas: Oncology, Rare Disease and Neuroscience. Our pipeline is fueled by internal and external innovation and supported by nearly 100 years of development experience and global hubs in the U.S., France and the U.K. Our teams in more than 40 countries and our partnerships around the world enable us to bring medicines to patients in more than 80 countries. For more information, visit ipsen.com
IQVIA is a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries and is dedicated to delivering actionable insights and accelerating innovations. As a trusted partner in clinical development, IQVIA helps accelerate new therapies to waiting patients. Our dedicated experts across IQVIA, IQVIA Biotech, and IQVIA Laboratories are here to discuss how we can support your oncology program.
At Jazz Pharmaceuticals, our purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with rare diseases - often with limited or no therapeutic options - so they can live their lives more fully. We have a diverse portfolio of marketed medicines including leading therapies addressing rare epilepsies, cancers and sleep disorders. Our patient-focused and science-driven approach powers pioneering research and development advancements across our robust pipeline of innovative therapeutics.
Johnson & Johnson is a global healthcare leader, committed to solving the toughest health challenges and transforming lives through research, development, manufacture and distribution of innovative medicines and medical technologies. The company’s Innovative Medicine business advances breakthrough science and develops transformational treatments in areas like oncology, immunology, neuroscience, and cardiopulmonary. In MedTech, the company is focused on developing and delivering cardiovascular, surgery, and vision solutions. Visit jnj.com to learn more.
Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company’s more than 67,000 employees serve clients in over 100 countries, worked on over 84% of the new drugs approved by the FDA in 2023 and performed more than 600 million tests for patients around the world.
We boast more than 80 years of history supporting what we do. A history built on trust and experience. A history based on integrity and transparency as key values for our success and for the pharmaceutical industry. We have state-of-the-art technology that allows us to offer complete product lines: Monoclonal antibodies, hormonal, osmotic, respiratory MDI, DPI, nasal spray, ophthalmic, liquid, semi-solid, solid, cosmetics and most pharmaceutical forms.
Lantheus is the leading radiopharmaceutical-focused company, delivering life-changing science to enable clinicians to Find, Fight and Follow disease to deliver better patient outcomes. Headquartered in Massachusetts with offices in New Jersey, Canada, Germany, Switzerland, Sweden and the United Kingdom, Lantheus has been providing radiopharmaceutical solutions for 70 years. For more information, visit www.lantheus.com.
Legend Biotech is the largest standalone cell therapy company and a pioneer in treatments that change cancer care forever. The company is at the forefront of the CAR-T cell therapy revolution with CARVYKTI®, a one-time treatment for relapsed or refractory multiple myeloma, which it develops and markets with Johnson & Johnson. Centered in the US, Legend is building an end-to-end cell therapy company by expanding its leadership to maximize CARVYKTI’s patient access and therapeutic potential.
Lunit develops AI-powered medical image analysis software via cutting-edge deep learning technology. Our systems can help physicians make accurate and efficient clinical decisions through data-driven imaging biomarkers.
Please come visit the ENCOMPASS Immersive Educational Experience, supported by an educational grant from Regeneron Pharmaceuticals Inc. Hear key clinical pearls from faculty experts across cancer types, engage in an augmented reality animation of cSCC, design a poster or clinical tap card for your practice setting, and converse with Ruby, the world’s first AI-driven clinical assistant for cSCC care.
Medscape Oncology is the leading online global destination for oncologists and healthcare professionals worldwide, offering the latest medical news and expert perspectives; essential point-of-care drug and disease information; and relevant professional education and CME
One of the leading healthcare organizations in Illinois, Memorial Health is a community-based, not-for-profit organization that provides a full range of inpatient, outpatient, home health, hospice, behavioral health and primary care physician services. With numerous sites of care throughout central Illinois, we deliver high-quality, patient-centered care in support of our mission to improve lives and build stronger communities through better health.
Stemline Therapeutics, a part of the Menarini Group, is focused on the development and commercialization of novel oncology therapeutics. The goal of our dedicated team of scientists, specialists, researchers, and developers is to build a leading biopharmaceutical company focused on improving the lives of cancer patients by developing and commercializing novel first-in-class therapeutics.
At Merck, our goal is to translate breakthrough science into innovative oncology medicines to help people with cancer. The potential to bring new hope to people with cancer drives our purpose and our commitment. As part of our focus on cancer, Merck is committed to clinical research with one of the largest development programs in the industry across more than 30 tumor types.
MERIT has provided image collection, centralized reading, and data management services for clinical trials since 2012. Our team has managed over 500 oncology studies across 25+ cancer types. MERIT's experts have extensive, cumulative experience with reading criteria across all phases of clinical research. MERIT values your partnership and will make your study a priority! Connect with our oncology team at oncology@meritcro.com or 608-509-7122
Moderna is one of the leaders in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made with the goal of transforming how we treat and prevent disease for everyone. For more than a decade we have been pioneering the potential of mRNA to develop therapeutics and vaccines for infectious diseases, immuno-oncology, and rare diseases.
Moffitt is dedicated to one lifesaving mission: to contribute to the prevention and cure of cancer. The Tampa-based facility is one of only 57 National Cancer Institute-designated Comprehensive Cancer Centers, a distinction that recognizes Moffitt’s scientific excellence, multidisciplinary research, and robust training and education. Moffitt’s expert nursing staff is recognized by the American Nurses Credentialing Center with Magnet® status, its highest distinction. For more information, call 1-888-MOFFITT (1-855-968-5798), visit MOFFITT.org
Myriad Genetics® is a leader in molecular diagnostic testing and precision medicine with offerings in oncology, women’s health and pharmacogenomics. Myriad tests and screenings provide personalized insights that help healthcare providers better prevent disease, assess disease risks, and guide treatment decisions. For more than 30 years, Myriad’s scientific expertise and innovation have brought actionable genetic insights to millions of patients.
Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach nearly 300 million people worldwide. Reimagine medicine with us: Visit us at https://www.novartis.com and connect with us on LinkedIn, Facebook, X/Twitter and Instagram.
Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating Fields. Novocure’s commercialized products are approved in certain countries for treatment of adult patients with glioblastoma, non-small cell lung cancer, malignant pleural mesothelioma and pleural mesothelioma. Novocure has several ongoing or completed clinical trials exploring the use of Tumor Treating Fields therapy in the treatment of glioblastoma, non-small cell lung and pancreatic cancer.
Nuvation Bio is a late-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates
The OSUCCC – James is the only cancer program that features a National Cancer Institute-designated comprehensive cancer center for 50 years with a freestanding cancer hospital aligned with a nationally ranked academic medical center on the campus of one of the nation’s largest public universities. With 21 floors, 414 beds and more than 1.1 million square feet, The James is the third-largest cancer hospital in the nation. Located in the rapidly expanding region of Columbus, Ohio, our vision is to create a cancer-free world, every person, every discovery, every time.
Onc.AI is a precision oncology AI company transforming cancer care decision making. Powered by a market leading real world dataset including imaging, EMR, genomics, and lab data, our AI models predict clinical outcomes across metastatic cancers, informing pharma development and clinical decision making (FDA pending). Trusted by 70% of top 15 pharma companies and partnering with Microsoft, Onc.AI is redefining oncology's future.
OncoHost is a technology company transforming the approach to precision medicine for improved patient outcomes. Its proprietary PROphet® platform is a plasma-based, proteomic pattern analysis tool whose initial offering in non-small cell lung cancer (NSCLC) uses a single blood sample to guide first-line immunotherapy decision-making, with a significant effect on overall survival. Backed by an experienced team and a large-scale clinical trial with over 40 sites and 1,700 patients worldwide, OncoHost is well-positioned to advance precision diagnostics and biomarker development to the next stage
Onviv bridges insights to impact through strategic expert engagement, technology-enabled collaboration, and real-world clinical intelligence. Powered by the Onviv platform and Onviv Expert Network, we help life sciences organizations access rapid, credible insights from leading healthcare professionals across academia and community practice. Our integrated ecosystem of services supports smarter decision-making across medical, commercial, educational, and strategic initiatives in healthcare.
OpenEvidence is an AI platform designed for physicians that delivers rapid, evidence-based answers to clinical questions. The platform synthesizes insights from more than 35 million peer-reviewed publications and trusted sources including New England Journal of Medicine, American Medical Association journals, and National Comprehensive Cancer Network guidelines. Used by hundreds of thousands of verified clinicians each month, OpenEvidence helps physicians quickly review medical literature, explore differential diagnoses, and access trusted evidence to support informed clinical decision-making.
At Personalis, we are transforming the active management of cancer through breakthrough personalized testing. We aim to drive a new paradigm for cancer management, guiding care from biopsy through the life of the patient. Our highly sensitive assays combine tumor-and-normal profiling with proprietary algorithms to deliver advanced insights even as cancer evolves over time. Our products are designed to detect MRD and recurrence at the earliest timepoints, enable selection of targeted therapies based on ultra-comprehensive genomic profiling, and enhance biomarker strategy for drug development.
Pfizer Oncology is at the forefront of a new era in cancer care. Our industry-leading portfolio and pipeline includes game-changing mechanisms of action to attack cancer from multiple angles, including antibody-drug conjugates (ADCs), small molecules, bispecifics and other immunotherapies. Driven by science, we are committed to accelerating breakthroughs to extend and improve the lives of people living with some of the world’s most common cancers.
PharmaMar is a biopharmaceutical company focused on the research and development of new oncology treatments, whose mission is to improve the healthcare of patients with our innovative medicines. The Company is inspired by the sea, driven by science, and motivated by patients. It is the world leader in marine medicinal discovery and development. PharmaMar commercializes Yondelis in Europe and Zepzelca in Switzerland by itself, as well as outside Europe with different partners for Yondelis, Zepzelca and Aplidin. In addition, it has a pipeline of drug candidates and a robust R&D oncology program.
Pierre Fabre Laboratories is a leading French medical and beauty care company with 4 decades of experience in innovation, development, manufacturing, and commercialization in oncology. The company dedicated about 80% of its R&D spendings to oncology in 2022 with a focus on targeted therapies. Its current commercial portfolio in oncology covers colorectal, breast and lung cancers, melanoma, hematology, and pre-cancerous skin conditions.
When Precision for Medicine’s name was chosen back in 2012, it signaled our commitment to a new movement shaping medical R&D, the movement to bring precision to the development of novel treatments. More than just a CRO, we bring precision to medicine by integrating biomarker capabilities, global CRO services, specialty and central labs, and in‑country regulatory expertise under one roof. Precision is solving the intricate challenges our clients face when developing new therapeutics and together, we are propelling medicine forward.
Predicine is a molecular insights company that has developed a breakthrough cfDNA + cfRNA-based comprehensive genomic profiling platform using blood/urine/tissue. It helps biopharmas accelerate biomarker-driven clinical trials in precision medicine.
Prestige Biopharma Limited is a rapidly growing biopharmaceutical company with an innovative platform spanning processes from discovery to manufacturing. The company is dedicated to developing first-in-class biologics and biosimilars with a strong focus on oncology and immunology. Prestige Biopharma is committed to developing novel treatments for life-threatening diseases as well as to improving accessibility and affordability of available targeted therapies paving the way to making a meaningful impact on patients' lives worldwide.
Haystack MRD® by Quest Diagnostics® is a tumor-informed, next-generation minimal residual disease (MRD) test that detects ultralow levels of circulating tumor DNA (ctDNA) to uncover residual or recurrent disease with superb accuracy. Based on more than 20 years of collaboration to advance technical and clinical development in liquid biopsy technologies by cancer genomics pioneers at Johns Hopkins School of Medicine, Haystack MRD delivers novel insights that can help shape personalized treatment decision-making and empower clinicians to improve patient lives.
Regeneron is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led for nearly 35 years by physician-scientists, our unique ability to repeatedly translate science into medicine has led to numerous FDA-approved treatments and candidates in development. Regeneron is accelerating and improving the traditional drug development process through our proprietary VelociSuite® technologies, and through research initiatives such as the Regeneron Genetics Center. Visit www.Regeneron.com to learn more.
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins.
Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing, and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer.
As one of the leading academic health systems in the nation, Rush delivers outstanding cancer services at our locations in Chicago, Oak Park, Oak Brook, Lisle and Aurora/Fox Valley. Rush University System for Health and The University of Texas MD Anderson Cancer Center announced a partnership to create RUSH MD Anderson Cancer Center. The partnership represents advanced clinical and operational integration in the delivery of cancer care, providing Rush patients greater access to cancer treatments and research considered among the best in the world.
Servier is a global leader in oncology focused on delivering meaningful therapeutic progress for the patients it serves. Governed by a non-profit foundation, Servier approaches innovation with a long-term vision, free of influence from investors and outside pressure to chase short-term monetary targets. With the company’s commercial expertise, global reach, scientific expertise and commitment to clinical excellence, Servier is dedicated to bringing the promise of tomorrow to the patients it serves.
Siemens Healthineers is elevating cancer care across the entire patient journey. We connect imaging, intelligent planning, and treatment delivery to enable precision therapy and support confident decisions at every step, from screening to survivorship. Cancer care is complex and under growing pressure. By enhancing the patient experience, enabling more personalized care, streamlining clinical workflows, and making innovation accessible, we help care teams deliver efficient, consistent, and patient-centered cancer care and expand capacity, improving outcomes for a world without fear of cancer.
Summit is an oncology, biopharmaceutical company focused on addressing critical unmet medical needs. Ivonescimab is a potential first-in-class investigational bispecific antibody combining immunotherapy (anti-PD-1) and anti-angiogenesis (anti-VEGF) mechanisms, showing cooperative binding with increased avidity in the tumor microenvironment. Summit’s ivonescimab Ph3 studies currently enrolling: NSCLC (NCT05899608, NCT06767514), colorectal cancer (NCT07228832). Ivonescimab is an investigational therapy not presently approved by any regulatory authority other than China’s NMPA.
Syncromune is a clinical-stage biopharmaceutical company developing SYNC-T, a platform immunotherapy designed to address major unmet needs & treatment challenges of incurable metastatic solid tumors. The SYNC-T solid tumor immunotherapy platform is personalized and performed completely in situ. The investigational therapy combines partial cryolysis to release tumor antigens followed by infusion of a multi-target drug directly into the tumor. This method is designed to help create conditions for T cell activation and a potential systemic anti-tumor response throughout the body.
Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company advancing innovative cancer therapies. Highlights of the Company’s pipeline include a menin inhibitor for R/R acute leukemia and a monoclonal antibody that blocks the CSF-1 receptor for chronic graft-versus-host disease. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, visit www.syndax.com or follow the Company on X and LinkedIn.
The mission of Taiho Oncology, Inc. is to improve the lives of patients with cancer, their families and their caregivers. The company specializes in the development and commercialization of orally administered anti-cancer agents for various tumor types. Taiho Oncology has a robust pipeline of small molecule clinical candidates targeting solid tumor and hematological malignancies, with additional candidates in pre-clinical development. Taiho Oncology is a subsidiary of Taiho Pharmaceutical Co., Ltd. which is part of Otsuka Holdings Co., Ltd. Taiho Oncology is headquartered in Princeton, NJ
At Takeda Oncology, we aspire to cure cancer, with inspiration from patients and innovation from everywhere. Our therapies for hematologic cancers and solid tumors have helped transform the treatment landscape for previously underserved patients. Building on this leadership, we are advancing a pipeline focused on the power of innate immunity. Our goal is to introduce new classes of immunotherapies that can lead to deep, durable responses so more patients can benefit from innovative medicines.
Telix is a global, commercial-stage biopharmaceutical company focused on the development of diagnostic and therapeutic (‘theranostic’) products using targeted radiation. Our products use targeted radiation to image disease and deliver truly personalized therapy in areas of significant unmet medical need. Telix’s theranostic pipeline aims to address significant unmet medical need in prostate, kidney, brain, and blood cancers, and a range of rare diseases.
AI-enabled precision medicine. Bringing the power of data and artificial intelligence to healthcare.
Hundreds of novel innovations enter clinical development each year, while biomarker testing complexity and costs surge. As healthcare shifts toward precision care, treatment decisions, monitoring strategies, and patient pathways increasingly rely on high-dimensional data and advanced diagnostics. Clinical diagnostics must keep pace with the scale and complexity of precision medicine, ensuring no patient is left behind. Waiv capitalizes on its industry-leading AI stack and clinically validated, AI tests to unlock morphological insights and future-proof the clinical diagnostic workflow.
1Cell.Ai, based in Foster City, California, is at the forefront of precision oncology, driving personalized cancer therapy with its innovative multi-omics technologies. Among its key advancements is the breakthrough single cell multi-omics platform, which allows for the comprehensive analysis of individual cancer cells including genomics, transcriptomics, and proteomics. Deep insights are provided into tumor heterogeneity, AI-enabled technology application in predicting homologous recombination deficiency, and revolutionizing Translational Research with true live single cell multi-omics.
A Cure in Sight supports families who have ocular melanoma and focuses on finding a cure. Through public and private partnerships, we provide education to support patients and their caregivers. ACIS educates the public about ocular melanoma, treatment options, clinical trials that may improve their prognosis, making it less overwhelming.
The Academy of Oncology Nurse & Patient Navigators, Inc. (AONN+) is the largest national specialty organization committed to growing and advancing the navigation profession. Since 2009, AONN+ has continuously worked to meet the professional needs of all navigators by developing educational resources, including standardized metrics, providing certification and continuing education hours, and offering an array of virtual and in-person networking and learning opportunities throughout the year.
Accessia Health is a national nonprofit 501(c)(3) organization that provides programs and services to those living with rare or chronic health conditions. With 90+ disease programs and over $1 billion in assistance distributed, we offer case management, education, and financial support for health insurance premiums, medication copayments, travel, and other essential medical expenses.
Accord BioPharma is a boutique specialty products company. At Accord BioPharma, we think beyond the expected. We go beyond biology with our INTAS heritage and 40 years of delivering high-quality oncology, immunology, and critical care therapies—with a humanizing twist—ensuring that the patient experience is at the core of everything we do.
Founded in 2018, Acrotech Biopharma Inc. was formed as a global platform to commercialize innovative proprietary medications. The company aims to launch scientifically advanced products to address unmet needs and deliver value to patients as well as all healthcare stakeholders. Acrotech aspires to be a patient focused, research-based organization that strives to launch treatments which are accessible to patients that need them.
Adium is a Latin American pharmaceutical company that produces, promotes and commercializes both primary care and specialty / oncology care therapies. Founded in 1971, Adium has subsidiaries in eighteen countries including Mexico, Brazil, Argentina and Central America with over 2000 pharmaceutical sales representatives. Adium represents international pharma and biotech companies in Latin America, such as BMS, Amgen, Astellas, Jazz Pharmaceuticals, Tolmar, Debiopharm and Meiji Seika,Japan.
The clinical development journey is complex, and finding an agile, consultative partner is critical. We offer optimized solutions from early-phase research to commercialization with CRO, FSP, and Strategic Resourcing services whilst driving the quality and validation of therapeutics - Delivering a better clinical experience.
Advanced CTS Corp. (ACTS), a drug wholesaler registered with the FDA in New Jersey, is committed to providing a comprehensive range of services for clinical research. Our services include Drug Depot Services, IP/PL Importing & Exporting, and Comparator/RLD Sourcing from regions such as North America, Europe, and Asia. At ACTS, we prioritize a client-centric approach, delivering the highest quality service while minimizing costs. With a diverse and multicultural team, we are well-equipped to serve clients from a wide range of countries and backgrounds.
Stop 5FU and capecitabine fatalities. DPYD genetic testing reduces suffering, saves lives, and saves money. Preemptive DPYD testing should be standard of care in US as it is in most of Europe. Together we can change the standard of care in the United States.
Agendia is a leading provider of innovative precision oncology solutions for early-stage breast cancer. Using advanced genomic assays like MammaPrint® and BluePrint®, they enable clinicians to quickly identify the most effective treatment plan, minimizing risks of over- and under treatment. Led by renowned scientists and oncologists, Agendia is dedicated to advancing genomic insights through ongoing research. Their FLEX Study, the world’s largest Real-World Evidence-based Breast Cancer database, aims to revolutionize precision in breast cancer management.
Akeso, Inc. (9926.HK), established in 2012, is a biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of new innovative antibody drugs that are affordable to patients worldwide. With fully integrated multi-functional platform, Akeso is internally working on a robust pipeline of over 50 innovative assets in the fields of cancer, autoimmune disease, inflammation, metabolic disease, and other major therapeutic areas. Akeso has successfully promoted the commercialization of seven innovative biological drugs (two out-licensed drugs).
Allucent has 30+ years of global experience offering comprehensive drug development solutions focused on small to mid-size biopharma, specializing in the design and execution of oncology and hematology clinical trials. Our expertise spans all development phases, from preclinical through Phase IV, with deep experience in solid tumors and hematologic malignancies and across advanced therapeutic modalities including radiopharmaceuticals, CAR T, and ADCs. Our integrated solutions include regulatory consulting, clinical pharmacology, modeling & simulation, biostatistics, and clinical operations.
For more than 50 years, the American Brain Tumor Association has been providing comprehensive resources that support the complex needs of brain tumor patients and their caregivers. The ABTA has invested over $38 million to advance discoveries and treatments and cultivate the next generation of brain tumor researchers.
ALCSI is a 501c(3) nonprofit dedicated to raising awareness for lung cancer and lung cancer screening. We work to promote the early detection of lung cancer by advocating for accessible screening for high-risk patients.
American Molecular Imaging (AMI) is proud to partner with oncology practices seeking high-quality, scalable tele-radiology support. Founded in 2012, AMI is a physician-owned platform delivering subspecialty imaging reads across oncology, molecular imaging, neurology, and cardiology, helping providers make faster, more confident clinical decisions, As a tele-radiology partner of choice, AMI combines clinical depth, national reach, and operational flexibility to help oncology practices enhance care delivery and keep pace with evolving demands.
With more than 18,000 members from nearly 100 countries, the American Society of Hematology (ASH®) is the world’s largest professional society dedicated to blood diseases. ASH supports clinicians and scientists working to conquer these conditions by advancing research, education, and advocacy. Through its award programs, meetings, publications, and educational resources, ASH promotes scientific discovery and improves care for patients worldwide.
Amgen harnesses the best of biology and technology to make people’s lives easier, fuller and longer. We draw upon our deep knowledge of science to push beyond what’s known today. We are one0of the world’s leading independent biotech companies – fighting the toughest diseases and helping millions of people globally.
A visionary diagnostic company dedicated to transforming the landscape of cancer care. 'Breaking Barriers to Precision Oncology' reflects our commitment to revolutionizing cancer diagnosis and treatment. We are driven by four fundamental values: Innovation in Care, Accessibility and Equity, Collaboration and Partnership, and Integrity and Trust. These values guide our pursuit of developing groundbreaking diagnostic tools and fostering a more equitable, collaborative, and trustworthy approach to oncology.
We are driven to outperform because we know our partners in the pharma industry require the best. And that’s what we provide. We build expert-led teams that deliver. Teams that integrate seamlessly as an extension of our clients’ own operations. Teams of dedicated, caring high-touch business and therapeutic experts. Teams that develop thoughtful and strategic plans — blueprints that are executed with seamless precision. We reliably deliver the highest possible ROI and the behavioral changes needed to drive success for our partners, for providers, and for patients. Quicker. Better. Nicer.
We are experts in Real World Databases. Our mission is to contribute to better patient care and to improving the well-being of individuals. Our job is to help healthcare manufacturers and practitioners optimize their decisions by supporting them with reliable insights. To do this, we collect healthcare data around the world and transform them using our technologies and our talents to give our customers strategic and operational guidance in order to improve the reliability of their decisions, achieving simplicity and clarity in our approach and in the solutions we offer.
We are the global market leader in evidence-based solutions for life science companies seeking to identify, develop, & commercialize oncology & hematology innovations. With a proven track record of success, we transform the growing scientific & clinical knowledge into better patient outcomes. The expertise of our team is backed by unparalleled access to global disease-state experts & healthcare professionals, making Aptitude Health the strategic partner of choice for life science companies.
Arcus Biosciences is a clinical-stage, global biopharmaceutical company developing first- or best-in-class medicines against well-characterized biological targets and pathways that have the potential to help people with cancer live longer. The company has advanced multiple investigational medicines into registrational clinical trials including casdatifan, a HIF-2a inhibitor for clear cell renal cell carcinoma, and quemliclustat, a small-molecule CD73 inhibitor for pancreatic cancer. For more information about Arcus Biosciences, please visit www.arcusbio.com.
Arima Genomics is redefining cancer diagnostics using whole-genome sequence and structure information. Arima’s assays are enabling a new era of comprehensive, clinically actionable therapy selection insight. The company serves oncologists through its CLIA-certified Aventa clinical testing laboratory in Orlando, Fla., and supports discovery-stage researchers worldwide with advanced kits and informatics. Learn more at aventatest.com and arimagenomics.com.
Founded in 2022, AACP is the largest oncology professional organization in Arkansas, comprising a powerful community of oncologists, nurse practitioners, physician assistants, pharmacists, and other multidisciplinary care providers who treat patients with cancer.
ArriVent is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. ArriVent seeks to utilize its team’s deep drug development experience to maximize the potential of its lead development candidate, firmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody drug conjugates, through approval and commercialization.
Artera is a global leader in precision medicine, leveraging multimodal artificial intelligence (MMAI) to personalize cancer care. Artera’s MMAI platform leverages a patient’s digitized histopathology images along with the patient’s clinical data to determine cancer aggressiveness and predict therapy benefit. This approach has been validated in multiple Phase 3 randomized trials across different cancers and is available in multiple versions across the globe. Artera’s headquarters is based in Los Altos, CA, while its CLIA-certified and clinical laboratory is located in Jacksonville, FL.
Ascentage Pharma Group is a global biopharmaceutical company engaged in developing novel therapies for various hematological disorders. The company has multiple on-going across clinical trials in all phases that involve the use of novel investigational agents such as third-generation tyrosine kinase inhibitors olverembatinib, Bcl-2 inhibitor lisaftoclax, , ALK inhibitor APG-2449, dual Bcl-2/Bcl-xL inhibitor pelcitoclax, and EED inhibitor APG-5918 to address unmet medical needs.
AVBCC is a 501(c)(6) organization dedicated to the education and exchange of knowledge among all stakeholders in the cancer care ecosystem responsible for patient care, to ensure optimal care is delivered to patients with cancer. The goal of AVBCC is to inform and educate all stakeholders: oncologists and hematologists, nurses, oncology nurse navigators, pathologists and geneticists, pharmacists, practice administrators, practice managers, patient advocacy organizations, managed care organizations, insurance companies, third-party payers, integrated health delivery systems, etc.
The Association of Cancer Care Centers (ACCC) provides education and advocacy for the cancer care community. Founded in 1974, ACCC is a powerful network of more than 40,000 multidisciplinary practitioners from over 1,700 hospitals and practices nationwide. As advances in cancer screening and diagnosis, treatment options, and care delivery models continue to evolve—so has ACCC—adapting its resources to meet the changing needs of the entire oncology care team.
ANCO (Association of Northern California Oncologists) was founded in 1990 to advocate, educate, and inform the practicing hematologist/oncologist to ensure delivery of the highest quality care to people living with cancer. We represent an expanding number of hematologists/oncologists throughout Northern California who practice in the community as well as at the regional academic centers—Stanford University, UC Davis, UC San Francisco—and The Permanente Medical Group.
Aurevia offers consulting services within medtech regulatory compliance, as well as clinical research CRO services supporting pharmaceuticals, ATMPs, biologics, medical devices, and in vitro diagnostic (IVD) devices. Our services for the healthcare, pharmaceutical, and medical technology sectors cover quality assurance, regulatory affairs, clinical studies, training, and more. Aurevia was formed in 2025 when Clinical Consulting, Scandinavian CRO, Artimed, P.R.I.S.M.A. CRO, QAdvis, Kasve, Mectalent Medical Services, Lean Entries, and part of Labquality merged.
Avance Clinical is a full-service Contract Research Organization (CRO) headquartered in Australia, with extensive operations across New Zealand, Asia, North America, and Europe. As the market leaders in Early Phase clinical trials, we leverage the unique advantages of the Australian market, including rapid ethics approval, no IND requirement, and the 43.5% R&D tax rebate, to provide biotechs with an accelerated pathway to clinical success. Specializing in world-class operations, we guide biotechs from early pre-clinical development through to late-phase studies.
Axiom Healthcare Strategies is a collaborative, life-sciences think tank that focuses on oncology and rare diseases. Axiom works together with industry and clinical leaders to provide cutting edge thought leadership to its clients and to support the advancement of the next generation of patient care.
Aya Locums is a leading locum tenens staffing company matching physicians & advanced practitioners with top facilities nationwide. We offer positions for physicians, physician assistants, CRNAs, NPs, dentists & more. With Aya Locums, you can expect complete transparency & exceptional service. We provide you with the tools & support to help you find the perfect opportunity that fits your goals & needs. Search nationwide jobs & view pay & assignment details, then engage with our concierge-level recruiters on your terms. It’s fast, simple & intuitive – the way a locum tenens experience should be.
Azurity specializes in providing innovative, high-quality medicines that serve overlooked patients. We supply a large number of products to treat a wide range of medical conditions. These include cardiovascular, central nervous system, endocrine, gastro-intestinal, anti-infective and oncology medicines. Many of our medicines are dose-form innovations for patients with needs that are not met by other available products. Our medicines have benefited millions of people
Baylor Scott & White is the largest not‑for‑profit health system in Texas, serving over three million customers through 53 hospitals, 1,300+ access points, and 59,000+ team members. With leading research, digital tools like MyBSWHealth, and award‑winning health plan solutions, the system delivers convenient, personalized care. Its mission, rooted in a century‑long ministry of healing, is to promote the well‑being of individuals and communities.
BC Cancer is a comprehensive cancer program that leads provincial planning and regional delivery of cancer care for the people of British Columbia, Canada. BC Cancer's mandate covers the full spectrum of cancer care, from prevention, screening, diagnosis and treatment, to research and education, to supportive care and palliative care. The Provincial Health Services Authority as a whole has over 24,000 employees and we hope that you will be one of them in the future!
Beacon Pharmaceuticals PLC is one of Bangladesh’s leading and fastest-growing pharmaceutical companies. Established in 2006, it is headquartered in Dhaka, Bangladesh, with a state-of-the-art 30-acre manufacturing plant in Bhaluka, Mymensingh. Beacon is widely recognized as the #1 oncology company in Bangladesh. It manufactures over 65 oncology products and is the first company in Bangladesh to export cancer drugs. The company produces over 400 generic drugs, including anti-cancer, cardiovascular, gastrointestinal, antibiotic, and neurological medications. for more mamun@beaconpharma.com.bd
The BESAFE Initiative works to address the growing global threat of substandard and falsified medical products through research, healthcare provider education, policy collaboration, and public health advocacy. Through its EveryDoseMatters campaign, BESAFE promotes awareness of cancer medicine safety and supports efforts to prevent and respond to poor-quality & falsified cancer medicines that place patients at risk of treatment failure and avoidable harm. EveryDoseMatters equips patients, healthcare providers, and caregivers with evidence-informed resources to support safer cancer medicine use.
Binaytara is a global oncology and continuing medical education (CME) nonprofit dedicated to reducing cancer health disparities. Binaytara organizes the most in-person oncology CME conferences in the United States, educating thousands of clinicians from 500 cancer institutions annually to improve their practice for their patients. Binaytara also published the International Journal of Cancer Care and Delivery, The Cancer News, and OncoBlast – an app that provides free CME. Join us: binaytara.org
Biocartis is an innovative molecular diagnostics company committed to revolutionize molecular testing with its unique proprietary Idylla(TM) platform. Biocartis’ proprietary molecular diagnostics (MDx) Idylla(TM) platform is a fully automated sample-to-result, real-time PCR system that offers accurate, highly reliable molecular information from virtually any biological sample, in virtually any setting, allowing fast and effective treatment selection and treatment progress monitoring.
Biodesix is a leading diagnostic solutions company, driven to improve clinical care and outcomes for patients. Biodesix Diagnostic Development Services - Our services enable the world's leading biopharmaceutical, life sciences, and research institutions with scientific, technological, and operational capabilities that fuel the development of diagnostic tests, tools, and therapeutics. Biodesix Diagnostic Tests - Our tests support clinical decisions to expedite personalized care and improve outcomes for patients with lung cancer.
We are a precision genomic medicine and biotechnology center specialized in genomic analysis, big data, and technology development for oncology and other complex therapeutic areas in Latin America and the US. We own molecular laboratories in Argentina, Mexico, and Brazil, plus a big data & technology office in San Francisco. We prioritize innovation through the integration of new technologies via our R+D department, and the development of technological platforms with AI. We also focus on new genetic studies at LatAm, with an established tumor biobank and the largest cancer dataset in
BioTouch is a single-source, national provider for every mission-critical kitting and logistics need. We partner with a wide range of medical facilities and healthcare providers to bring a broader, bigger, and better level of care to healthcare delivery. Our uniquely integrated service capabilities help you simplify healthcare delivery, spanning medical kit and supply distribution, printing, logistics, temperature control, and last-mile services.
The Bladder Cancer Advocacy Network, or BCAN, was founded in 2005 and provides patients with the critical information and community support they need to thrive today – and champions innovative research and responsive national policy to inspire hope for tomorrow.
We are Blood Cancer United, and we believe everyone with blood cancer deserves a longer, better life. That’s why we are on a mission to cure blood cancer and improve the quality of life of all patients and their families. How? We fund life-saving blood cancer research around the world, provide free information and support services for patients and their families, and are the voice for those seeking access to quality, affordable, coordinated care. With your help, we have invested more than $2 billion in groundbreaking research supporting many of today's most innovative approaches to treatment
Blue Faery's mission is to prevent, treat, and cure primary liver cancer, specifically hepatocellular carcinoma (HCC), through research, education, and advocacy.
Blue Spark Technologies is a leader in developing thin, flexible, wearable remote patient monitoring solutions. Pioneering continuous vital sign monitoring solutions that improve patient care, reduce costs and readmissions, Blue Spark’s flagship products, TempTraq® and VitalTraq™, are changing the way the world looks at vital signs. TempTraq has been clinically proven to detect Cytokine Release Syndrome 28.2 hrs earlier than the standard of care in immunotherapy patients, and fevers 18.5 hrs earlier than the standard of care in patients with confirmed blood infections.
Bradford Hill is a regional leader clinical cancer research center located in Santiago, Chile, South America. Over the past 15 years thousands of cancer patient without treatment options have been treated with cutting edge biological molecules and immunotherapy receiving clinical benefit and hope. Bradford Hill data has contributed to the completion of pivotal clinical trials mainly in solid tumors. Our goal as organization is to bring the most promising studies into the region and be innovators and partners with the companies in the development of new clinical trials.
Burning Rock Dx (NASDAQ: BNR) is a global precision oncology leader specializing in NGS-based tissue and liquid biopsy diagnostics. With internationally labs (CLIA, CAP, ISO15189, ISO13485), the company provides in-house assays and integrated solutions. It partners with biopharma and clinical labs to support trials, biomarker research, and CDx development. Achievements include one NMPA-approved IVD kits, four CE-marked assays, one PMDA-approved CDx System and FDA/NMPA Breakthrough Device Designations for its multi-cancer early detection test.
Caidya is a global, full-service CRO, aligned with biopharma innovators. We bring clinical trial expertise relevant to your studies, agility to navigate complex trials, and global access to patients, yielding the high-quality data you need to make informed decisions – today, and tomorrow.
Cancer and Careers was founded in 2001 to support every person, in every industry and every job so they can thrive in their work and their life after a diagnosis. CAC's services include a comprehensive website and library of publications in English and Spanish; career coaching; resume review; financial and technology grants; access to experts for one-on-one support; and educational events for people with cancer and their caregivers, healthcare providers and coworkers. CAC also works with companies to develop their internal systems of support for employees navigating illness and work.
CSC uplifts and strengthens people impacted by cancer by providing support, fostering compassionate communities, and breaking down barriers to care. CSC is a global nonprofit network with over 200 locations, including CSC and Gilda's Club centers as well as healthcare partnerships.
CANCER101 is a patient advocacy organization that's on a mission to simplify healthcare—one person at a time—through personalized education, navigation and support. To fulfill our mission, CANCER101 was founded in 2002 to 1) support people with cancer and their care partners with a comprehensive roadmap to help navigate next steps 2) personalize the patient experience through tailored education that's based on personal preferences, and 3) address unmet needs through solutions co-designed with patients, care partners and clinicians.
For over 80 years, CancerCare has empowered millions of people affected by cancer through free counseling, resource navigation, support groups, educational resources, advocacy and direct financial assistance. Our oncology social workers improve the lives of people diagnosed with cancer, caregivers, survivors and the bereaved by addressing their emotional, practical and financial challenges.
Cardinal Health Real-World Evidence and Insights uncovers actionable insights through deep data and unique research methodology. Through our Oncology Provider Extended Network (OPEN) and Practice Research Network (PRN), we can support your oncology real-world data and evidence needs. Our robust access to community practices, where much of patient care occurs, empowers you to understand product outcomes in real-world patient populations.
Castle Biosciences is a leading diagnostics company improving health through innovative tests that guide patient care. We aim to transform disease management by keeping patients and clinicians first. Our innovative tests for skin cancers, uveal melanoma, Barrett’s esophagus and mental health conditions provide personalized, clinically actionable information to clinicians and patients to guide treatment decisions and improve health outcomes. (www.CastleBiosciences.com)
Certara accelerates medicines using biosimulation software, technology, and services to transform traditional drug discovery and development. Its clients include more than 2,400 biopharmaceutical companies, academic institutions, and regulatory agencies across 70 countries.
The Cholangiocarcinoma Foundation (CCF) is a leading nonprofit dedicated to improving the lives of those affected by cholangiocarcinoma—a rare, aggressive bile duct cancer. CCF addresses critical gaps in awareness, research, and patient support. With over $3M in research grants awarded and seven FDA-approved therapies supported, CCF is driving real change for those affected by this disease. Learn more at curecca.org. Hope in Research. Strength in Community.
Headquartered in Wilmington, DE, ChristianaCare is one of the country’s most dynamic health care organizations, centered on improving health outcomes, & innovating to make high-quality care more accessible and affordable. ChristianaCare includes an extensive network of primary care and outpatient services, home health care, urgent care centers, three hospitals (1,430 beds), a freestanding emergency department, a Level I trauma center and a Level III NICU, a comprehensive stroke center and regional centers of excellence in heart and vascular care, cancer care cancer care and women’s health.
CHRISTUS Health is a not‑for‑profit, mission‑driven health system delivering compassionate, high‑quality care across Texas, Louisiana, and New Mexico. CHRISTUS Trinity Clinic, a 1,700‑provider multispecialty group, offers a collaborative, physician‑led culture supported by strong primary care, subspecialty depth, and advanced hospital services. We provide mission‑aligned Hematology/Oncology opportunities, multidisciplinary support, and system investment to expand and elevate cancer care in high‑need communities.
Chugai is a research and development-oriented pharmaceutical company with unique technology and science as its strengths. In collaboration with Roche, we are committed to continuously generating innovation with the aim of continuously providing patients with innovative drugs and services.
City of Hope is among America’s largest and most advanced institutions for cancer research and treatment. With a more than 110-year legacy of serving humanity, we are an independent academic institution fueled by a trailblazing spirit and enduring community support. Our national network is noted for groundbreaking discoveries, world-renowned cancer specialists, and being ranked among the nation’s top cancer centers by U.S. News & World Report. We are relentlessly optimistic in pursuing our biggest goal: Making hope a reality for all touched by cancer and related serious diseases.
Clario is a leading provider of endpoint data solutions to the clinical trials industry, generating high-quality clinical evidence for life sciences companies. We offer comprehensive evidence-generation solutions that combine medical imaging, eCOA, precision motion, cardiac and respiratory endpoints. Our global team of science, technology, and operational experts have supported over 60% of all FDA drug approvals since 2012.
Cleveland Clinic Cancer Institute provides comprehensive cancer care through a multidisciplinary approach, with internationally recognized research efforts that align with the NCCN and NCI standards. Recognized for its expertise and utilizing the most effective techniques, the Cancer Institute offers access to cutting-edge clinical trials and support programs across Northeast Ohio, Florida, London and Abu Dhabi. The Cancer Institute aims to help cancer patients improve their quality of life and achieve long-term survival.
The CLL Society is dedicated to addressing the unmet needs of individuals living with CLL and SLL by offering patient education, advocacy, support, and research. We encourage you to refer your patients to www.CLLSociety.org for more information. Additionally, the CLL Society provides healthcare providers with complimentary printed educational materials upon request through our Clinician Resource Library. For further details, please visit www.cllsociety.org/cll-society-clinician-resource-library/.
CMIC Group, the first CRO in Japan, offers full services, including drug development and manufacturing, clinical trial, site management, to sales and marketing. Today, we are involved in close to 80% of new drug development and filing in Japan. Our oncology experts will help you determine the best strategy in accordance with Japan/Asia specific changing regulations and unique environment, working flexibly with your company’s plans for market entry. We will navigate the regulatory hurdles and accelerate your clinical trials by making the right connections with our established network of KOLs.
Cogent Biosciences, Inc. is a biotechnology company focused on developing precision therapies for genetically defined diseases. The company is preparing to launch bezuclastinib, a potential best-in-class KIT inhibitor, for patients with Advanced and NonAdvanced Systemic Mastocytosis (SM) and for patients with Gastrointestinal Stromal Tumors (GIST). In both indications bezuclastinib has been granted Breakthrough Therapy Designation. In addition, the Cogent Research Team is developing a pipeline of novel therapies targeting mutations in ErbB2, PI3K, KRAS and JAK2.
Cogitars provides biostatistical consulting, data visualization, and statistical programming, focusing on small and mid-sized biotech and pharma companies. We are experts in Bayesian trial designs such as BLRM and BOIN, supporting clients across oncology areas including solid tumors, hematological malignancies, and multiple myeloma, with a focus on early clinical phases. We support in all clinical phases, starting from preclinical and Phase 1/2, 3 and HTA as Lead Statisticians, DMC members, or specialized consultants. We are a German company supporting clients worldwide. Open to investors
Coherus is focused on developing and commercializing a diversified portfolio of immuno-oncology therapies. The advancement of multiple clinical stage candidates underscores our commitment to immuno-oncology treatments. About Coherus Solutions™ Coherus is committed to supporting patients with reimbursement and support programs that offer limited out of pocket costs or patient assistance for eligible patients. More specific information can be found on CoherusSolutions.com
The College of American Pathologists offers two monthly publications: CAP TODAY and the Archives of Pathology & Laboratory Medicine. CAP TODAY brings monthly business and medical news in the clinical laboratory. The Archives of Pathology & Laboratory Medicine is one of the best-read journals among pathologists and laboratory directors. Samples are available.
The Colorectal Cancer Alliance empowers a nation of passionate and determined allies to prevent, treat, and overcome colorectal cancer in their lives and communities. Founded in 1999 and headquartered in Washington, D.C., the Alliance advocates for prevention through initiatives like LEAD FROM BEHIND, magnifies support with BlueHQ, and accelerates research through Project Cure CRC. We are the largest national nonprofit dedicated to colorectal cancer, and we exist to end this disease in our lifetime. For more information, visit colorectalcancer.org.
Cooler Heads debuts Amma, the first FDA-cleared, portable scalp cooling system. Founded by Kate Dilligan, breast cancer survivor and entrepreneur, based off her own experience with cold caps, Amma offers an easy-to-use mechanical system, empowering patients and caregivers. It seamlessly integrates scalp cooling into symptom management, relieving burden on infusion centers and enhancing the patient experience. Cooler Heads works to protect the agency, identity, and privacy of patients impacted by the effects of cancer treatment.
For over 25 years, Corcept’s focus on cortisol modulation and its potential to treat patients with a wide variety of serious disorders has led to the discovery of more than 1,000 proprietary selective cortisol modulators. Corcept is conducting advanced clinical trials in patients with hypercortisolism, solid tumors, ALS and liver disease. In February 2012, the company introduced Korlym®, the first medication approved by the U.S. Food and Drug Administration for the treatment of patients with endogenous hypercortisolism. Corcept is headquartered in Redwood City, California.
Welcome to Cracking Cancer, the podcast that bridges the gap between patients and healthcare providers. Our mission is twofold: to empower listeners with clear, accessible insights into cancer care and to raise funding for vital cancer research. Through expert interviews, patient stories, and listener Q&A, we break down complex topics, challenge cultural barriers, and foster a more informed, supportive cancer community. Join us as we crack cancer together—one conversation at a time. Donate to CC: giving.cu.edu/crackingcancer Donate to Concannon Lab: giving.cu.edu/egfr
Creative Portal for Oncology Education and More (CPOEM) Foundation is a non-profit initiative by practicing oncologists to help spread knowledge about cancer, its treatment and care. Led by renowned experts and leaders in Oncology in collaboration with the some of the best oncology centres in the world. Our vision is to be the oncology education and knowledge platform of choice for patients, cancer care providers and healthcare professionals. Our mission is to provide easy to consume cancer awareness content and certify aspiring oncologists, clinicians and the larger provider community.
Creatv provides the following blood tests applicable to all solid tumors, all stages of cancer and all therapies. Creatv’s blood tests can screen for cancer and provide prognosis at the same time. -Screen for single cancer or pan cancers -Detect minimal residual disease at end of therapy -Detect recurrence earlier than imaging Creatv’s blood tests can also provide many diagnostic applications. -Predict treatment response to new therapy just 30 days after first therapy -Companion/complementary diagnostics -Prognosis -Provide copious unfragmented tumor DNA for sequencing
Curium is a world-class nuclear medicine solutions provider. With manufacturing facilities across Europe and the United States, Curium supports over 14 million patients around the world with SPECT, PET and therapeutic radiopharmaceuticals to provide potentially life-saving diagnostic solutions. The Curium brand name is inspired by the work of radiation researchers Marie and Pierre Curie and emphasizes our focus on nuclear medicine.
We’re committed to supporting patients and their caregivers in every way we can. They are at the heart of everything we do. We focus on providing treatments and services for patients with neurological, rare metabolic, and rare immunological conditions, most of which are genetic conditions. We also provide a treatment for patients with rare types of leukemia. We’re headquartered in Cambridge, UK and have staff working across the US, with an office in Detroit, MI.
Founded in 1993, the Dakota Oncology Society (DOS) is the largest oncology professional organization in the state. DOS is a State Affiliate of the American Society of Clinical Oncology. Our members receive valuable educational content and innovative resources designed to keep them ahead of the local and national challenges and trends directly impacting the high-quality care their patients deserve.
Dana-Farber Cancer Institute in Boston is an internationally recognized leader in cancer care, research, and innovation. Founded by Sidney Farber, the father of modern chemotherapy, we are a founding member of the Harvard Cancer Consortium, an NCI-designated Comprehensive Cancer Center. Dana-Farber pairs groundbreaking science with compassionate care, with 1,200+ active clinical trials and 600,000+ outpatient visits annually. From 2020–2024, Dana-Farber science contributed to the development of over 50% of new FDA-approved cancer drugs and cell therapies. Learn more at booth 10007.
Daniels Health partners with oncology centers and hospitals to deliver safe, compliant management of chemotherapy, RCRA hazardous, trace chemo, and pharmaceutical waste. Our clinically designed reusable containment systems support USP compliance, reduce staff exposure risk, and enhance infection control. Through safety, data visibility, reliable service, transparent pricing, and sustainability-driven solutions, Daniels helps cancer care providers protect their teams, patients, and the environment while controlling costs.
The Dear Jack Foundation provides impactful programs benefiting adolescents and young adults (AYA) diagnosed with cancer and their families to improve their quality of life from treatment to survivorship. Our vision is to be a national leader in adolescent and young adult cancer programming, by giving patients, survivors, and their caregivers a community and support rooted in mental and physical wellness based tools and resources from diagnosis through survivorship.
Clinical Education Alliance (CEA) is a global leader in innovative and impactful healthcare education, insights and communications, empowering healthcare professionals with the tools and resources they need to stay current and improve patient outcomes. CEA sets the standard for professional development with its commitment to scientific rigor, innovative formats, sophisticated marketing, and engagement techniques grounded in adult learning principles. With its expansive reach across the healthcare team, CEA drives healthcare excellence across the care continuum.
Delcath Systems (NASDAQ: DCTH) is a specialty pharmaceutical and medical device company focused on treating primary and metastatic liver cancers. Our Melphalan/HDS system delivers high‑dose chemotherapy directly to the liver while limiting systemic exposure. In Europe, the CE‑marked CHEMOSAT® system is commercially available, with 250+ treatments at 20+ centers. We’re advancing U.S. late‑stage development, including the FOCUS study in ocular melanoma, and exploring additional orphan liver cancer indications.
Delphi Diagnostics Inc. is a Texas-based company focused on advancing clinically valid tests for the prognosis and prediction of breast cancer treatment. Delphi Diagnostics, Inc. holds an exclusive license from MD Anderson Cancer Center in Houston, TX, to commercialize the Endocrine Activity Index(EAI), a technology that was developed by the laboratory of Dr. W. Fraser Symmans. EAI measures endocrine activity in stage II-III, HR+HER2- breast cancer. Delphi's vision is to make the EAI test available to breast cancer patients and open new pathways for personalized breast cancer treatment.
The Denali Oncology Group is a organization whose primary mission is to promote, plan, support, represent, advocate for, and conduct educational, and scientific activities to facilitate improvements in the practice of oncology and the delivery of care to patients for the benefit of the citizens and residents of the State of Alaska.
Disc Medicine is a clinical-stage biopharmaceutical company committed to discovering, developing, and commercializing novel treatments for patients who suffer from serious hematologic diseases. We are building a portfolio of innovative, potentially first-in-class therapeutic candidates that aim to address a wide spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, specifically heme biosynthesis and iron homeostasis.
Founded in 2010, Doximity is the leading digital platform for U.S. medical professionals. The company's network members include more than 80% of U.S. physicians across all specialties and practice areas. Doximity provides its verified clinical membership with digital tools built for medicine, enabling them to collaborate with colleagues, stay up to date with the latest medical news and research, manage their careers and on-call schedules, streamline documentation and administrative paperwork, and conduct virtual patient visits.
Dr. Reddy’s Laboratories Ltd. is a global pharmaceutical company headquartered in Hyderabad, India. Established in 1984, we are committed to providing access to affordable and innovative medicines. Driven by our purpose of ‘Good Health Can’t Wait’, Dr. Reddy’s offers a portfolio of products and services. Oncology is one of our major therapeutic areas of focus. Our major markets include USA, India, Russia & CIS countries, China, Brazil, and Europe. Dr Reddy's is the partner of choice for more than 15 global multi-national companies in oncology and other therapy areas.
Early Access Care is a full-scale specialist service provider of oncology Expanded Access & Compassionate Use programs, ranging from protocol and program development, end-to-end operational management, Real World Data services, and a variety of customized service offerings. We work with biotech and pharmaceutical companies to set up and manage programs in the pre-approval space, including post-trial access, managing all regulatory and logistical aspects of early access.
Eikon Therapeutics is a clinical stage company exploring new dimensions in biology by transcending disciplines. We have assembled a team with expertise in drug discovery, clinical development, data analytics, and engineering and are working together to purposefully integrate science and advanced engineering to create innovative therapies with the potential to improve and extend life. We have active clinical programs with observed activity in the treatment of solid tumors, as well as a robust pipeline of discovery programs in Oncology, Immunology and Neuroscience progressing toward the clinic.
Elephas is developing an oncology platform to predict response to immunotherapy that utilizes live tissue from a biopsy. Our innovative technology measures immunotherapy response from a live tumor over time. The platform is tumor-agnostic and designed to evaluate treatment across indications and immunotherapies. Making us uniquely positioned to predict response to immunotherapy within 72 hours of biopsy, before treatment begins.
Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help more than 51 million people across the globe. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable.
Emerald Clinical is a global, full-service CRO with over 25 years of experience delivering end-to-end clinical trial solutions. Headquartered in Singapore, we support Phase I–IV and real-world studies across all therapy areas through a team of 800+ professionals working in 40+ countries, backed by a collaborative network spanning 70+ locations worldwide. We partner with more than 160 biotech companies and 15 of the world’s top 20 pharmaceutical firms, providing scientific excellence and operational expertise to advance innovative therapies.
Founded in 2017, the Empire State Hematology & Oncology Society (ESHOS) is the largest oncology professional organization in New York. Formally known as the New York State Society of Medical Oncologists & Hematologists, ESHOS unifies the educational needs of cancer care professionals from upstate to downstate, and brings together the multidisciplinary membership of the Hematology-Oncology Managers of New York and Upstate New York Society of Medical Oncology and Hematology.
Cincinnati-based Enable Injections is a global healthcare innovation company developing and manufacturing drug delivery systems designed to improve the patient experience. Enable's body-worn enFuse® delivers high-volume pharmaceutical and biologic therapeutics via subcutaneous administration, with the aim of improving convenience, supporting superior outcomes, and advancing healthcare system economics. Approved in the United States in combination with a specific drug, more information: https://enableinjections.com/our-products.
We are a patient advocacy org that focuses on educating patients and caregivers on all treatment options, advanced diagnostics and clinical trials to allow the patient to make informed decisions regarding their brain cancer, brain tumor or metastatic disease to the brain treatment journey. We connect patients directly to appropriate specialists to enable access to novel treatment options in hopes of optimizing their overall survival as well as their sustained quality of life. All services provided are free to the patient and the caregivers.
End Lung Cancer Now (ELCN) is an initiative of the Indiana University Melvin and Bren Simon Comprehensive Cancer Center focused on ending lung cancer in Indiana. ELCN mobilizes advocates, clinicians, researchers, and communities to advance prevention and risk reduction, expand access to lifesaving lung cancer screening, accelerate research participation, and support patients and families throughout all stages of their lung cancer journey.
At enGene we aim to make genetic medicine mainstream by developing non-viral therapeutics that are delivered directly to mucosal tissues and other organs. Our mission is to deliver innovative, non-viral medicines to improve the quality of life for people with urological cancers—starting with non-muscle invasive bladder cancer (NMIBC) and expanding beyond. We are developing innovative solutions with the goal of reducing treatment burden and improving patient outcomes.
Entia is an oncology services provider unlocking the full potential of cancer therapy through at-home blood monitoring. They have developed Entia Liberty®, the world’s first at-home blood analyser, enabling cancer patients to perform routine assessments at home and unlocking preventative models of care. Partnering with leading healthcare providers in the UK and US, Entia delivers proactive, patient-centric care and enhances care pathways for novel therapeutics.
Founded by health professionals and programmers, we've worked with physicians since 1979. Epic builds integrated software that connects care with a single record. Built-in evidence-based tools give physicians the information they need to deliver better care - and to measure how well they're doing.
The European Cancer Organisation is a not-for-profit federation of 40 Member Societies working in cancer at a European level, together with 21 European Patient Advisory Committee members. The Organisation is dedicated to convening oncology professionals and patients to agree on policy, advocate for positive change, and speak for the European cancer community. The European Cancer Organisation is the organiser of the annual European Cancer Summit.
Everest Clinical Research is a global, full-service CRO with 20+ years of oncology experience. In the past 5 years, our teams have supported 200+ solid & hematologic malignancy trials, across innovative/adaptive designs, including dose escalation/expansion. Our experience spans gene/cell therapies, small molecules, & antibodies. Founded as a biostats & data management provider, Everest brings deep biometrics expertise to clinical development. Our teams apply a data-driven approach to study design & execution, translating deep understanding of trial data into robust, decision-ready outcomes.
Exai Bio is a next-generation liquid biopsy company with a mission to enable a world where cancer can be detected early, diagnosed accurately, treated in a personalized and targeted way, and ultimately cured. The company’s proprietary RNA- and AI-based liquid biopsy technology delivers actionable clinical insights into cancer biology, detecting even the smallest tumors at the earliest stages of disease.
Exelixis is innovating next-generation medicines and regimens at the forefront of cancer care. We are rapidly evolving our product portfolio to target an expanding range of tumor types and indications with our clinically differentiated pipeline of small molecules, antibody-drug conjugates and other biotherapeutics.
FDA's Bad Ad Program is an outreach program designed to help healthcare providers recognize potentially false or misleading prescription drug promotion. The program’s goal is to raise awareness among healthcare providers including physicians, physician assistants, nurse practitioners, nurses, pharmacists, pharmacy technicians, and trainees about potentially false or misleading prescription drug promotion while also providing them with an easy way to report it to the Agency.
Fennec Pharmaceuticals is a biotechnology company dedicated to improving the lives of children with cancer who experience hearing loss as a result of chemotherapy.
For patients, caregivers, and families affected by colorectal cancer, Fight CRC is the leading empowerment and advocacy organization working to provide hope and healing through a supportive, informed community. Fight CRC relentlessly pursues the most promising research endeavors and takes bold action to impact policy change.
Since 2005, the nonprofit Firefighter Cancer Support Network (FCSN) has provided assistance and one-on-one mentoring to thousands of cancer-stricken firefighters and their families. FCSN also delivers extensive firefighter cancer awareness and prevention training nationwide.
Flatiron Health is a healthtech company expanding the possibilities for point of care solutions in oncology and using data for good to power smarter care for every person with cancer. Through machine learning and AI, real-world evidence, and breakthroughs in clinical trials, we transform patients’ real-life experiences into knowledge and create a more modern, connected oncology ecosystem. Flatiron Health is an independent affiliate of the Roche Group.
FLASCO is a member-supported state oncology society dedicated to education, timely information sharing, and professional support for Florida’s oncology care teams. By bringing together clinicians across disciplines, FLASCO fosters collaboration and knowledge exchange that ultimately benefits patients. Like any hero, every oncology professional needs a sidekick. FLASCO serves as a trusted partner and advocate, leading state legislative efforts, championing cancer research, and supporting initiatives that advance oncology care and develop future leaders.
Fore Biotherapeutics is a precision oncology company dedicated to developing innovative treatments that provide a better outcome for patients with cancer. Our lead investigational candidate is plixorafenib (PLX-8394; FORE-8394), a novel selective BRAF inhibitor with activity against BRAF Class I (V600) and Class II (non-V600) alterations. In a phase 1/2a study, plixorafenib showed good tolerability and prolonged tumor responses and disease control in solid tumors with BRAF V600 mutations and BRAF fusions. A phase 2 basket study in BRAF-altered solid tumors (NCT05503797) is currently enrolling.
Fortrea is a leading global CRO for oncology clinical development and patient access solutions to biopharmaceutical, medical device and diagnostic companies. Fortrea’s strength leverages over three decades of global trial management experience with over 1250 oncology studies in the last 5 years. These include full-service phase I-IV clinical trial management, clinical pharmacology, technology-enabled trial solutions and post-approval services. We have a passion for scientific rigor that drives innovation and accelerates the availability of life changing therapies for patients in need.
Fosun Pharma USA Inc., based in Princeton NJ, is led by a team of highly experienced executives with strong track records from leading US and European pharmaceutical companies both in commercial operations and R&D. Fosun Pharma USA today markets a portfolio of specialty pharmaceutical injectable products and ophthalmic and has a pipeline of innovative products. With its core commercial team in place, Fosun Pharma USA is building its commercial presence in the US market.
Fred Hutch Cancer Center unites individualized care and advanced research to provide the latest cancer treatment options while accelerating discoveries that prevent, treat and defeat cancer and infectious diseases worldwide. Based in Seattle, Fred Hutch is an independent, nonprofit organization and the only National Cancer Institute-designated cancer center in Washington.
Fulgent is a technology-based company focused on transforming care. Our Fulgent Oncology offerings include genomic profiling for solid tumors and hematologic malignancies, hereditary cancer testing, and anatomic pathology services. For those in need of lab services for research, our BioPharma Services team provides everything you need for projects in multiomics, oncology, liquid biopsy, and more. At Fulgent we have the technology and expertise for your needs, all under one roof.
GammaTile® is an FDA‑cleared, bioabsorbable collagen implant embedded with radiation seeds for patients with operable brain tumors. Placed in the surgical cavity at tumor removal, it delivers immediate, targeted radiation to treat residual cancer cells while limiting exposure to healthy brain tissue. Since its U.S. market launch in March 2020, GammaTile has been adopted by more than 100 leading treatment centers.
Gastric Cancer Foundation improves the lives of people affected by gastric (stomach) cancer by supporting patient education initiatives and innovative research studies to improve treatments and ultimately, find a cure.
Genetron Health is China’s leading precision oncology platform company, specializing in cancer molecular profiling research and applications. Our primary areas of expertise are companion diagnostic partnerships in biopharma solutions and central lab testing services. There are high-quality standard and customized assays based on multi-omics that could well hasten the approval of anti-drug therapies. Our goal is to finally eradicate cancer by utilizing cutting-edge genomics technology for cancer detection and therapy.
Precision Oncology News is a daily email newsletter launched in 2019 to cover the application of genomic sequencing and other biomarker-driven approaches to guide cancer treatment. Precision Oncology News is published by GenomeWeb, an independent online news organization based in New York. Since 1997, GenomeWeb has served the global community of scientists, technology professionals, and executives who use and develop the latest advanced tools in molecular biology research and diagnostics. GenomeWeb is a family brand of Crain Communications.
GTC provides comprehensive genomic profiling of DNA, cfDNA, RNA, and cfRNA for solid and hematologic cancers worldwide. We offer tissue, blood, CSF liquid biopsy, and cutaneous sample testing with a 5–10 day turnaround and
Geron is a late-stage clinical biopharmaceutical company focused on development and commercialization of therapies in hematologic malignancies. We are committed to pursuing discoveries with the potential to extend and enrich the lives of patients.
Driven by innovation & accessibility, Glenmark Pharmaceuticals stands among the world's leading pharmaceutical companies, transforming healthcare and delivering life-changing medicines across 80+ countries. With a five-decade strong legacy in branded, innovative, and generics products, we lead cutting-edge research across key therapies, including oncology, respiratory, and dermatology. In alliance with Ichnos Glenmark Innovation (IGI), we are pioneering next-generation oncology research to address critical patient needs and pushing boundaries of science to deliver breakthrough treatments.
The Global Colon Cancer Association (GCCA) advocates for equitable access to quality colorectal cancer screenings, testing, treatments, and care, because where you live should not determine whether you can prevent or survive colorectal cancer. As both a membership-based umbrella organization and a patient advocacy organization, GCCA works toward this goal by amplifying and supporting the efforts of our member organizations, by developing adaptable advocacy and educational materials for our members, and by conducting our own advocacy, education, and initiatives.
The Global Resource for Advancing Cancer Education (GRACE) provides expert-mediated information on current and emerging cancer management options in order to empower patients, caregivers, and health professionals to become direct partners in cancer care.
Guardant Health is a leading precision oncology company focused on helping every person live a life free from cancer. Founded in 2012, Guardant is transforming cancer care by providing critical insights into what drives the disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve patient outcomes across all stages of cancer, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the best treatment for patients with advanced cancer.
Hamamatsu Corporation, the North American subsidiary of Hamamatsu Photonics K.K., brings seven decades of photonics expertise to medical and life science imaging. Our technologies span sensors, detectors, cameras, and light sources, delivering stable, reliable performance. MoxiePlex™ advances spatial biology with automated multispectral imaging, enabling high-quality, reproducible data from complex tissue samples. By simplifying multiplex workflows and preserving spatial context, it empowers deeper insights and supports next-generation research and precision medicine.
Harvest Integrated Research Organization (HiRO) is a globally oriented, innovative CRO. With global operations and integrated capabilities, HiRO provides a full range of cross-border solutions and services to its clients, including early pre-clinical strategic planning, clinical trial design, regulatory, pharmacovigilance, statistics, data management, end-to-end project management, and clinical and medical monitoring services. HiRO strives to work collaboratively with biotech and pharmaceutical companies to bring new products from the laboratory to the market.
HSCO strives to promote the highest professional standards of oncology in the state through member-driven educational programs, peer-to-peer networking opportunities, and collaboration with local organizations and industry trailblazers.
Haymarket Oncology publishes Cancer Therapy Advisor, Oncology Nurse Advisor, and Hematology Advisor. These websites offer oncology health care professionals a comprehensive knowledge base that includes research news, guideline updates, long-form reporting, drug information, and clinical tools. Haymarket Oncology’s mission is to provide each member of the oncology care treatment team with the resources and information they need to make informed decisions and effectively manage patients throughout the treatment continuum.
Head for the Cure is a non-profit organization that aims to build awareness for brain tumors, raise funds for brain cancer clinical trials and research, and ignite hope & joy for the brain tumor community.
Health Volunteers Overseas improves the availability and quality of health care through the education, training, and professional development of the health workforce in resource-scarce countries. HVO envisions a world where all people have access to high-quality health care delivered by local health professionals.
The Health, Hope & Hip-Hop Foundation is committed to helping Black Americans eliminate the healthcare disparities that are taking their lives in disproportionate numbers.
HealthTree is a nonprofit building trusted patient communities to accelerate research and drive cures for all cancers. We use clean, validated patient records from EHR data and patient-reported outcomes. Our AI matches patients to treatments, clinical trials, and genetic twins. Patients use our conversational AI, named Leif, to help them understand their records. Doctors can scan a QR code for instant access to a patient’s medical summary. We’ve built a registry with 16,000 blood cancer patients and have now expanded and are building a solid tumor registry, free for all researchers to access.
The HealthWell Foundation is a leading independent non-profit dedicated to improving access to health care for America’s underinsured. When health insurance is not enough, we fill the gap by assisting with copays, premiums, deductibles and out-of-pocket expenses. We awarded over $1.1 billion in grants in 2025. Since 2004, we have helped more than 1.3 million patients afford essential treatments and medications. HealthWell is recognized as one of America’s most efficient charities — 100 percent of every dollar donated goes directly to patient grants and services.
Hoosier Cancer Research Network (HCRN) is a non-profit CRO that supports early-phase, multi-center, investigator-initiated clinical trials. We facilitate these trials through our network of over 100 academic and community clinical research sites across the United States. Currently, HCRN manages more than 70 studies, representing 55 sponsor-investigators from 33 institutions, with support from 35 funders. Our clinical trial working groups, where new concepts are discussed and developed into exceptional clinical trials, engage the participation of more than 500 investigators.
Hospital Information Services for Jehovah's Witnesses | United States is part of an international network distributing authoritative, clinical information regarding strategies to avoid allogeneic blood transfusion. Additionally, we provide a resource for health-care personnel managing patients who decline blood transfusions. These services are provided without charge.
HPV Cancers Alliance is a 501(c)(3) non-profit organization whose mission is to empower individuals with knowledge about the health and lifestyle impact of HPV infection and embolden them to take the necessary action to prevent and treat the virus and eliminate its consequences. As the only organization focused on all six HPV-associated cancers, we strive to reduce the burden of HPV-related diseases through education, advocacy, and prevention.
ICON plc is a world-leading clinical research organisation. Offering deep operational and medical expertise we accelerate innovation, driving emerging therapies forward to improve patient outcomes. From molecule to medicine, we deliver integrated consulting, clinical development, commercialisation and post-marketing solutions to pharmaceutical, biotechnology, medical device and government and public health organisations. With headquarters in Dublin, Ireland, ICON employed approximately 39,800 employees in 95 locations in 55 countries as of September 30, 2025.
IDEAYA Biosciences is a precision oncology company focused on improving lives through transformative medicines to address cancers with significant unmet need. Guided by a precision-first, biomarker-driven approach, we are building a diversified pipeline of potential first-in-class clinical programs. Our lead asset, darovasertib, targets the key oncogenic driver of uveal melanoma and is progressing across metastatic and neoadjuvant settings, with the goal to prolong outcomes and preserve vision. IDEAYA is also advancing its robust clinical stage pipeline across multiple solid tumor-types.
At Illumina, our mission is to improve human health by unlocking the power of the genome. Our sequencing by synthesis chemistry is used to generate high-accuracy DNA and RNA sequence data in studies around the globe. Through innovation and collaboration, we have developed CGP tools that help investigators identify biomarkers, describe tumor biology, and inform therapy selections. The opportunity to transform tumor profiling with innovative assays, new companion diagnostics, and liquid biopsy tools inspires us to push the boundaries of what is possible and drive innovation.
Imagene AI is a pioneer in multimodal foundation models for precision medicine, advancing translational research and clinical development. Our Cross-Modality Intelligence Engine, delivered through the OI Suite, integrates real-world data including histopathology images, multi-omic data, longitudinal clinical records to derive meaningful, biologically grounded insights, generate and validate biomarker hypotheses, and increase predictive power in low-data settings. We make every trial more responsive, every insight more actionable, and every patient journey more personalized. Founded in 2020 an
The Immune Oncology Research Institute (IMMONC) is dedicated to advancing cancer research through innovative clinical trials and international collaborations. Our booth highlights IMMONC’s investigator-sponsored studies and expanding research opportunities in Armenia, where an efficient regulatory environment and strong research infrastructure facilitate high-quality clinical trials. Visit us to explore collaboration opportunities and access a diverse patient population for impactful oncology research.
Immunome is a clinical‑stage oncology company developing first‑ and best‑in‑class targeted therapies to improve outcomes for cancer patients. Our pipeline includes varegacestat, a gamma secretase inhibitor in a Phase 3 trial for desmoid tumors; IM‑1021, a ROR1‑targeted ADC in Phase 1; and IM‑3050, a FAP‑targeted radioligand with IND clearance. We are also advancing several preclinical ADCs against undisclosed solid‑tumor targets.
The Indiana Oncology Society (IOS) represents the common interests of oncologists and hematologists treating cancer in Indiana. We provide educational programs, networking opportunities, and robust advocacy support to help practices stay ahead of the shifting healthcare landscape and meet the challenges that directly impact how they care for their patients.
Inhibrx is a clinical-stage biopharmaceutical company focused on developing a broad pipeline of novel biologic therapeutic candidates in oncology and orphan diseases. Inhibrx utilizes diverse methods of protein engineering to address the specific requirements of complex target and disease biology, including its proprietary protein engineering platforms. For more information, please visit www.inhibrx.com.
France's leading cancer center, the Institut Curie combines an internationally renowned research center with a state-of-the-art hospital complex that treats all cancers, including the rarest. Founded in 1909 by Marie Curie, the Institut Curie brings together over 3,800 researchers, doctors and caregivers around its 3 missions: care, research and teaching. It is a charitable foundation authorized to receive donations and legacies. Thanks to the support of its donors, the Institut Curie is able to accelerate discoveries and thus improve treatments and patients' quality of life.
Intermountain Health is the largest nonprofit health system in the Intermountain West. We’re dedicated to creating healthier communities and helping our patients thrive.
The International Brain Tumour Alliance (IBTA) is a global network founded in 2005 as a dynamic worldwide community for brain tumour patient organisations and others involved in the field of neuro-oncology. The IBTA brings together experience and expertise from all over the world with the aim of enhancing the well-being and quality of life for brain tumour patients and their families. By working together with many individuals and organisations we identify collaborative actions across the international community and work towards our vision of a world free from the fear of brain tumours.
The International Myeloma Society (IMS) promotes education, research and clinical care globally by: building a global myeloma community; educating for today and the future; fostering clinical and translational research in myeloma; assuring clinical excellence worldwide.
Invivoscribe® is a technology-driven international company focused on precision diagnostics with best-in-class products and services that optimize patient care and accelerate drug approvals worldwide. We offer molecular assays, reagents, controls and bioinformatics that are used by researchers and clinicians for diagnosis, prognosis and monitoring. Our international LabPMM® network, located in the US, Europe and Asia, offers standardized flow cytometry and NGS services focused on actionable biomarkers supporting stratification, therapeutic decisions, MRD testing and CDx development.
Invivyd is a biopharmaceutical company on a mission to rapidly and perpetually deliver antibody-based therapies that protect vulnerable people from the devastating consequences of circulating viral threats, beginning with SARS-CoV-2. Invivyd’s technology works at the intersection of evolutionary virology, predictive modeling, and antibody engineering, and is designed to identify high-quality, long-lasting antibodies with the potential to resist viral escape. Visit invivyd.com to learn more.
The Iowa Oncology Society (IOS) is the premier community for oncology professionals in Iowa, uniting physicians, advanced practitioners, pharmacists, nurses, and other cancer care specialists. Founded in 1992, IOS provides education, advocacy, and collaboration to support high quality, patient centered oncology care. The society offers conferences, resources, and policy engagement to help members stay informed and elevate cancer care across the state.
We are a community of patients, survivors, volunteers, supporters, health and social care professionals and researchers. Together we are transforming the experiences and outcomes of people affected by cancer through our advocacy, support services and research.
ITM is a leading radiopharmaceutical biotech company dedicated to providing a new generation of radiodiagnostics and therapeutics. With improved patient benefit as the driving principle for all we do, ITM advances a broad precision oncology pipeline, including multiple Phase 3 studies, combining the company’s high-quality radioisotopes with a range of targeting molecules. By leveraging our two decades of pioneering radiopharma expertise, ITM strives to provide patients with more effective targeted treatment to improve clinical outcomes and quality of life.
"The Japanese Society of Medical Oncology” (abbreviated as JSMO)is organized to contribute to the public welfare through the improvement of the treatment of cancer. To this end, the Society shall research, study, and disseminate domestic and international information relating to the medical treatment of cancer for patients with cancer, their family members, and cancer researchers; shall promote and encourage the improvement of medical techniques for cancer; and shall engage in various business activities to keep in contact and cooperate with related organizations.
The Hackensack Meridian John Theurer Cancer Center at Hackensack University Medical Center is a premier NJ cancer center known for comprehensive cancer care, research, and expertise. It has 16 specialized divisions, a dedicated team, and serves more patients in the NJ/NY area than any other facility. JTCC offers advanced care, expanded to Jersey Shore University Medical Center, Toms River Regional Cancer Center and Saint Joseph's Health. Learn more at www.jtcancercenter.org.
Jupiter Medical Center is a leading provider of high-quality, safe, patient-centered care in Palm Beach County and the Treasure Coast. Named a 2023 Leapfrog “Top General Hospital” and the only hospital in its region with a 4-star CMS quality and safety rating, it offers advanced physicians, modern facilities, and specialty services including orthopedics, cancer, cardiac, neuroscience, women’s and children’s care, and urgent care.
KaSCO strives to promote the highest professional standards of oncology in the state through member-driven educational programs, peer-to-peer networking opportunities, and collaboration with local organizations and industry trailblazers.
Kapadi: Bridging the Gap Between Expertise & Accessibility Kapadi, the premier global oncology CRO, tailors solutions to advance your research. We enhance clinical trial efficacy with expert teams, innovative technologies & strong site relationships. Our extensive North American, European & APAC site network provides access to essential, diverse study populations. With offices worldwide, we offer expertise in all oncology areas, specializing in complex biologics & CTx modalities. Kapadi's unwavering commitment to excellence ensures your research needs are met with utmost precision & quality.
Karyopharm Therapeutics is a commercial-stage pharmaceutical company pioneering novel first-in-class cancer therapies and dedicated to the discovery, development, and commercialization of drugs to treat cancer. We are recognized leaders in XPO1 inhibition. We believe in the extraordinary – in the dedication to positively impact patient lives and treat cancer.
The Kentucky Society of Clinical Oncology (KYSCO) was organized in 1999 as a 501(c)6 medical society to promote advocacy, education and communication for oncologists and other members of the multidisciplinary cancer care team.
For more than 30 years, the Kidney Cancer Association has stood for excellence in research and education as well as the thoughtful, patient-driven services we extend to the patients and caregivers who have placed their trust in us. Our mission is to be a global community dedicated to serving and empowering patients and caregivers, and leading change through advocacy, research, and education.
King Hussein Cancer Foundation and Center (KHCF/KHCC) is the largest community-based organization fully dedicated to combating cancer in Jordan and the region and a leader in raising awareness on the importance of early detection and cancer prevention. It provides world-class treatment and achieves survival rates comparable to those of leading cancer treatment facilities across the globe. KHCC has received various international accreditations among these was the first institution in the developing world to be accredited by the Joint Commission International as a disease-specific cancer center.
Founded by a three-time cancer alumna, Kits to Heart (@kitstoheart) gives thoughtfully designed, curated cancer care kits to patients and their caregivers. Kits are shipped directly to families nationwide and dropped off at hospitals and cancer centers. Kits to Heart also provides an innovative Art for Cancer Wellness Program to address the issue of loneliness and help patients, caregivers, and oncology healthcare workers heal through art.
Klein Hersh is a precision executive search firm with over 25 years of proven success delivering the visionary leaders shaping the future of life sciences and healthcare. Our experienced team of dedicated experts is deeply immersed in every facet of pharma, biotech, and healthcare, and has developed trusted relationships with far-reaching talent networks. By bringing our signature ambition and passion to every search, we efficiently and consistently deliver top talent to accelerate life sciences and healthcare innovation, enrich culture, and contribute lasting impact to client organizations.
Kognitic AI provides an advanced analytics platform for oncology intelligence. The platform integrates clinical trials, publications, regulatory filings, and standard-of-care data into a unified AI system that enables teams to benchmark clinical outcomes, analyze competitive landscapes, and identify strategic opportunities across the oncology pipeline. Pharmaceutical organizations use Kognitic to accelerate evidence-based decision making in drug development, business development, and commercial strategy.
KoNECT, established in 2007, is an affiliated organization of the Korean Ministry of Health and Welfare, committed to the development of Korea's clinical trial infrastructure, and the promotion of its capabilities to attract more global trials to Korea. KoNECT supports all international pharmaceutical and biotech sponsors planning to conduct clinical trials in Korea. Major services and features include: provision of comprehensive clinical trial related information(e.g., patient distribution data, clinical trial site, and investigator information).
The Korean Society of Medical Oncology (KSMO) is a professional oncology society dedicated to advancing cancer care through education, research, and delivering optimal care for cancer patients. By fostering effective communication among oncologists and researchers, KSMO actively supports the professional growth of oncologists, uniting their expertise to enhance patient outcomes. KSMO serves as a vital source of evidence-based cancer information for patients and contributes to the continuous advancement of cancer treatment and research.
Our mission is to realize the promise of precision medicines to help patients with cancer lead better, longer lives. Our novel therapies are designed to target cancer cells selectively, increasing clinical benefit while moving the field forward in areas with the highest unmet needs. Just as vital to our mission, we’re investigating our novel therapies in combination with standards of care, forging new paths to give patients a better chance for long-term durable remissions.
Online press publisher.
LFSA is dedicated to a world without inherited cancer. LFS A provides a wide range of information, advocacy, and support services for individuals and families with Li-Fraumeni Syndrome. We support a consortium of researchers, medical providers, and caregivers to further research and promote optimal care for the LFS community. We are a community of Li-Fraumeni Syndrome families and survivors. We are the building blocks of a future without LFS. Together we will bridge the gap between patients and professionals who have the same goal. We are global and strive to support LFS families worldwide.
Lifescience Dynamics is a global decision support firm helping our clients make better strategic decisions through insight and foresight. Founded in 2004 and headquartered in London with offices worldwide, we specialise in Market Research, Competitive Intelligence, Market Access, and Strategic Advisory, powered by a diverse and collaborative team.
Which everyday cancer problem will we fix today? Our mission is centered around this one question. We make immediate impact on the lives of people affected by cancer and seek out solutions to support quality of life today—and for every step of the journey.
The need has never been greater to connect great clinicians and great healthcare facilities. That’s what we do. Every day. We’re LocumTenens.com. We connect clients and clinicians to take care of patients. How do we do it? By doing it better than everyone else. Whether you’re looking for a locum tenens job or locum tenens coverage, our experienced agents have the specialized knowledge, know-how, and personal relationships to take care of you and your search.
Lone Star Oncology | Oncology Education | Accredited Continuing Education (CME/CNE/NCPD/CPE) | Professional Development | Oncology Meetings (Conferences, Symposiums & Seminars)
LOS represents the common interests of oncologists and hematologists treating cancer in Louisiana. We provide educational programs, networking opportunities, and robust advocacy support to help practices stay ahead of the shifting healthcare landscape and meet the challenges that directly impact how they care for their patients.
The mission of the Lung Cancer Research Foundation (LCRF) is to improve lung cancer outcomes by funding research for the prevention, diagnosis, treatment and cure of lung cancer.
LUNGevity Foundation is the leading nonprofit that’s transforming how people are diagnosed and live with lung cancer through research, education, and support. We accomplish this by driving research that better detects and treats lung cancer; removing barriers and accelerating access to care; generating patient insights through data; and connecting the global lung cancer community.
Man Up to Cancer is a non-profit organization dedicated to helping men avoid isolation during their cancer journeys. We offer peer-to-peer support, an annual retreat, chemo backpack program, and local chapters — all geared toward improving the quality of life of our members, and changing the way men go through cancer.
Manifold enables research organizations of all sizes to advance data-driven discovery. Leading institutions, including the Broad Institute, the American Cancer Society, and the Indiana University Melvin and Bren Simon Comprehensive Cancer Center, rely on Manifold to make high-value data more accessible and usable. Our AI-powered Trusted Research Environment (TRE) accelerates research by streamlining data management, advanced analytics, machine learning, and secure collaboration at scale.
Massive Bio’s vision is to cover entire Pharma value chain with disruptive solutions to improve entire ecosystem from drug development to commercialization. Massive Bio is a unique tech-enabled big data platform with multiple use cases — addressing all friction points in end-to-end patient journey, enabling access to advanced treatment options for patients and optimizing drug commercialization for pharma. Massive Bio is utilizing AI to enhance equitable access and precision targeting for clinical trial matching, drug matching, and drug development in 12 countries.
McKesson Corporation is a diversified healthcare services leader dedicated to advancing health outcomes for patients everywhere. We work with biopharma companies, care providers, pharmacies, manufacturers, governments, and others to make quality care more accessible and affordable. Our portfolio of oncology businesses provides research, insights, technologies, and services that put patients first. Together, McKesson’s The US Oncology Network and Ontada power cancer innovation, value-based care and better patient outcomes.
Medable is on a mission to get effective therapies to people faster. Its digital clinical trials platform enhances speed, scale, and patient access in clinical research, accelerating medicines for thousands of conditions without treatment or cure. Named a Leader in the industry by Everest Group and awarded Best Digital Health Solution by the Galien Foundation, the Medable platform has been deployed in more than 300 trials in 60 countries and 120 languages, serving more than one million patients globally. Medable is a privately held, venture-backed company headquartered in Palo Alto, California
Median Technologies helps conquer cancer by extracting clinical insights from patients’ medical images. Median’s iCRO central and AI enhanced imaging services help life sciences companies drive their oncology clinical studies toward successful approval. We deliver unmatched operational excellence and reliability and leverage the latest in AI-powered imaging to develop actionable insights, accelerating the development of life-saving cancer treatments worldwide.
MOASC is a leading professional organization dedicated to empowering oncology professionals through advocacy and education, standing as a trusted voice and vital resource for the cancer care community. MOASC supports more than 700 hematologists and oncologists working in both local communities and major academic centers.
Founded in 1824 in Charleston, the Medical University of South Carolina is the state's only comprehensive academic health system. Our mission is to preserve and optimize human life in South Carolina through education, research and patient care. The Division of Hematology & Oncology at MUSC builds upon a long history of excellence in hematology and hematological malignancies, as well as solid tumor oncology and bone marrow transplant. MUSC's Hollings Cancer Center (HCC) is the state's only National Cancer Institute (NCI)-designated cancer center.
Medidata is powering smarter treatments and healthier people through digital solutions to support clinical trials. Celebrating 25 years of ground-breaking technological innovation across more than 35,000 trials and 11 million patients, Medidata offers industry-leading expertise, analytics-powered insights, and the largest patient-level historical clinical trial data set in the world. More than 1 million users trust Medidata’s seamless, end-to-end platform to improve patient experiences, accelerate clinical breakthroughs, and bring therapies to market faster. Discover more atwww.medidata.com.
Medlive is the leader in learner engagement and educational design for clinicians, patients and caregivers seeking dynamic, up-to-date and accurate medical education. Medlive provides trusted digital health education from leading specialists and advocacy/partner organizations to empower audiences to make informed medical decisions that lead to better health outcomes.
Medpace is a scientifically-driven, global, full-service clinical contract research organization (CRO) providing Phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. Medpace’s mission is to accelerate the global development of safe and effective medical therapeutics through its high-science and disciplined operating approach that leverages local regulatory and deep therapeutic expertise across all major areas including oncology, cardiology, metabolic disease, endocrinology, central nervous system and anti-viral and anti-infective.
Menarini Silicon Biosystems offers FDA cleared and laboratory-developed tests (LDTs) used to detect and analyze circulating tumor cells of epithelial origin in human blood with CELLSEARCH®. In addition, MSB offers comprehensive genomic profiles with MenariniSearch. These minimally invasive liquid biopsy tests enable optimized patient care and comfort throughout the patient’s therapeutic journey. In addition, MSB offers the patented CellSave™ and CellRescue tubes, which stabilize cells and allow for a 96 to 120 hour window from sample collection to testing, at room temperature.
The Mesothelioma Applied Research Foundation (Meso Foundation) is a nonprofit organization that funds mesothelioma research, provides support services to patients, educates the public, and advocates for governmental funding for mesothelioma research. The foundation focuses on improving diagnosis, treatment, and finding a cure for this cancer.
MIB Agents Is A Leading Pediatric Osteosarcoma Nonprofit Dedicated To Making It Better For Our Community Of Patients, Families, Medical Professionals, Researchers, And Industry Partners Through Programs, Education, And Research.
The Michigan Society of Hematology and Oncology is a physician organization representing medical oncologists, hematologists, and radiation oncologists in our state. It is the mission of MSHO to promote exemplary care for patients with cancer and blood disorders through advocacy, education, and research.
MSCO strives to promote the highest professional standards of oncology in the state through member-driven educational programs, peer-to-peer networking opportunities, and collaboration with local organizations and industry trailblazers.
MOS strives to promote the highest professional standards of oncology in the state through member-driven educational programs, peer-to-peer networking opportunities, and collaboration with local organizations and industry trailblazers.
MJH Life Sciences® is the leading health care engagement network and home to OncLive®, Targeted Oncology™, PER®, AJMC®, CancerNetwork®, CURE®, CGTLive®, PTCE, Pharmacy Times®, and Mesmerize®. We offer academic & community oncologists, nurses, patients, and all involved with the cancer care journey an unmatched selection of resources to help improve outcomes. Our content integrity ensures our audience receives objective information in addition to expert insights. Our events, videos, conference coverage, podcasts, POC displays, and more help educate the cancer care community.
Founded in 2015, the Montana State Oncology Society (MSOS) is the largest oncology professional organization in the state. MSOS comprises a powerful community of oncologists, nurse practitioners, physician assistants, pharmacists, and other multidisciplinary care providers involved in the treatment of patients with cancer.
The Multinational Association of Supportive Care in Cancer (MASCC) is an international, interdisciplinary organization dedicated to practice, research & education. Our mission is to continually improve supportive care of people with cancer - from diagnosis through to survival or end-of-life care - and each of our members plays a role in making this happen. Stay up-to-date with latest advances in supportive care through exclusive educational events, resources, and access to our scientific journal, Supportive Care in Cancer Join today and save 50%. Use code: ASCO25 (for new members only)
We empower women to understand their breast density and cancer risk. Most don’t know dense tissue increases cancer risk or that standard screening misses many cancers. My Density Matters, founded by Leslie Ferris Yerger after her stage IV diagnosis following an ‘all clear’ mammogram, provides education and tools to help women learn their density, explore screening options, and advocate for proper breast cancer screening.
Signatera is a personalized, tumor-informed, molecular residual disease (MRD) test for patients previously diagnosed with cancer. Custom-built for each individual, Signatera uses circulating tumor DNA to detect and quantify cancer left in the body, identify recurrence earlier than standard of care tools, and help optimize treatment decisions. Signatera is available for clinical and research use and has coverage by Medicare across a broad range of indications. Signatera has been clinically validated across multiple cancer types with published evidence in more than 100 peer-reviewed papers.
The National Blood Clot Alliance is a 501(c)(3), nonprofit, voluntary health organization dedicated to advancing the prevention, early diagnosis and successful treatment of life-threatening blood clots such as deep vein thrombosis and pulmonary embolism. NBCA works on behalf of people who may be susceptible to blood clots, including but not limited to, people with clotting disorders, cancer, and risks related to surgery, immobility, child birth and birth control. NBCA accomplishes its mission through programs that build awareness, educate patients and clinicians, and promote supportive policy.
National Brain Tumor Society (NBTS) unrelentingly invests in, mobilizes, and unites the brain tumor community to discover a cure, deliver effective treatments, and advocate for patients and caregivers. Building on over 30 years of experience, we are the largest patient advocacy organization in the United States committed to curing brain tumors and improving the lives of patients and families. With thousands beside us, our collective voices and actions are a powerful force for progress
The National Comprehensive Cancer Network® (NCCN®) is a not-for-profit alliance of 33 leading cancer centers devoted to patient care, research, and education. NCCN is dedicated to improving and facilitating quality, effective, equitable, and accessible cancer care so all patients can live better lives. For Clinicians: NCCN.org For Patients: NCCN.org/patients
NORD® is the only independent U.S. organization working at the intersection of care, research and policy for all rare diseases. The Rare Cancer Coalition, formalized in 2017 as a program under the NORD Membership umbrella, unites advocacy organizations working in rare cancers to collaborate on issues facing their communities.
NCODA is a leading non-profit organization dedicated to empowering cancer care professionals to deliver positive, patient-centered outcomes through leadership, expertise, quality standards, and best practices. NCODA believes that the coordination of care facilitated through a medically integrated approach enhances quality by engaging all stakeholders on the care team, reduces the opportunity for waste and errors, and avoids needless costs to patients.
NeoGenomics specializes in cancer genetics testing and information services, providing one of the most comprehensive oncology-focused testing menus to help physicians diagnose and treat cancer. We offer a differentiated solution driven approach to tumor profiling using multiple modalities to detect genomic alterations in clinically significant driver genes centered on NGS, FISH and IHC. NeoGenomics partners with pharmaceutical clients from discovery to commercialization with broad oncology testing capabilities powered by in-house scientific expertise and dedicated project support teams.
Founded in 1993, the Nevada Oncology Society (NOS) is the largest oncology professional organization in the state. NOS comprises a powerful community of oncologists, nurse practitioners, physician assistants, pharmacists, and other multidisciplinary care providers involved in the treatment of patients with cancer.
The New Mexico Society of Clinical Oncology (NMSCO) brings together oncologists and oncology focused healthcare professionals across the state to advance high quality cancer care. Founded in 2020, NMSCO provides education, networking, and strong advocacy to help practices navigate evolving clinical and policy challenges. As a state chapter of ACCC and an ASCO affiliate, NMSCO supports multidisciplinary teams with resources that improve patient outcomes statewide.
Norstella is a global pharma intelligence provider bringing together leading organizations—Citeline, Evaluate, MMIT, Panalgo, and The Dedham Group—with a shared goal of helping bring life-saving therapies to market faster. Together, we deliver critical insights that support smarter strategic and commercial decisions across the drug development lifecycle. Our solutions help clients assess market needs, prioritize portfolios, connect patients to clinical trials, manage risk and compliance, and build successful launch strategies using advanced analytics, real-world data.
The North Carolina Oncology Association (NCOA), founded in 1993, is a statewide multidisciplinary community of oncology professionals dedicated to advancing high quality, patient centered cancer care. As an affiliate of ASCO, and a state chapter of ACCC , NCOA provides education, advocacy, and collaborative resources that help clinicians navigate clinical, operational, and policy challenges while supporting excellence across the cancer care continuum.
Northside Hospital Cancer Institute (NHCI) has established a reputation of excellence in oncology. We have become one of the largest and most respected providers of cancer care in the Southeast with services provided at over 60 locations. NHCI is accredited by the American College of Surgeon’s Commission on Cancer as an Integrated Network Cancer Program and is recognized for providing high-quality, comprehensive cancer care including screening, diagnosis, research, precision medicine treatment, and support services.
The Lurie Cancer Center at Northwestern Medicine is leading efforts to translate life-changing research into better ways to prevent, diagnose and treat cancer. Collaborating across disciplines, our physicians and scientists combine scientific discovery and medical expertise to provide the highest level of innovative, patient-centered care. We are committed to training and mentoring the next generation of leaders, ensuring equity in cancer care, and improving the lives of people with cancer.
Nucleo develops automated CT & MRI image analysis tools for oncology workflows. Our platform integrates with standard PACS infrastructure and delivers quantitative outputs without manual intervention. Core capabilities include: - Body composition assessment (SMA, SMI, VAT, SAT, IMAT); - Sarcopenia detection - Tumor segmentation according to RECIST criteria - Tumor longitudinal analysis - Tumor classification
State Oncology Society, physician based (must be a physician working in Ohio to become a member), includes oncology professionals within the physician's group/practice. 220 physician members - 1100 in total membership - Mission - to address barriers to quality cancer care.
Olema is a clinical-stage biopharmaceutical company focused on transforming the metastatic breast cancer treatment paradigm and improving outcomes for patients living with breast cancer and beyond. We are advancing our pipeline of novel therapies by leveraging our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Founded in 2006, Olema is headquartered in San Francisco, California and has operations in Cambridge, Massachusetts.
At Oncentric, our vision is to transform the way oncology care is delivered by making advanced, personalized, and efficient cancer treatment accessible to all. We believe that oncology practices of all sizes should have access to the same level of cutting-edge technology and comprehensive support that large healthcare systems enjoy. Whether you’re a small clinic serving a local community or a large cancer center treating patients from across the region, Oncentric is here to ensure that you have everything you need to provide the best possible care.
ONCOassist is a free mobile and desktop app designed to support oncology healthcare professionals in everyday clinical practice. Used by over 105,000 clinicians worldwide, ONCOassist provides fast and reliable access to oncology specific calculators, treatment tools, clinical decision aids, and reference information in one place. The app helps streamline decision making, reduce cognitive load, and support high quality patient care. ONCOassist is continually updated in collaboration with oncology experts to ensure clinical relevance and real-world usability.
OncoLens is an oncology-focused digital health platform that enhances cancer care through AI-driven analytics and multidisciplinary collaboration tools. By leveraging multiple data types, OncoLens improves patient outcomes and revenue opportunities by identifying patients for clinical trials and biomarker testing. The platform's analytics help cancer centers pinpoint patient and revenue leakage, conduct cohort analyses, and support accreditation. The OncoLens Research Network collaborates with industry partners to bring curated research and real world evidence initiatives to cancer centers.
The Oncology Nursing Society (ONS) is a professional association of more than 35,000 members committed to promoting excellence in oncology nursing and the transformation of cancer care. ONS creates value and enhances oncology nursing staff performance, through accessing ONS originally produced, exclusively evidence-based, and continuously updated clinical content, the backbone of all ONS educational and instructional materials. Courses, books, and other ONS products are available for organizations to purchase at group rates with volume discount pricing.
Oncoscope is a comprehensive medical decision-support tool developed by oncology scientists and AI experts. It conducts daily Cochrane-level literature reviews supported by an agentic system of large language models, extracting 32 key variables from each relevant oncology publication into a structured database. 100% human reviewed and cross-checked, the results are integrated with treatment paths from national guidelines and cross-linked with FDA and clinical trial registries. Designed for oncology professionals, we offer individual and institution subscription options.
OneMedNet is revolutionizing how the world unlocks Real-World Data (RWD), harnessing the untapped potential of over 2,130 healthcare sites through its iRWD™ platform. This isn’t just data—it’s the lifeblood of innovation, from de-identified medical imaging to electronic health records, fueling breakthroughs for drugmakers, medical device pioneers, and AI visionaries. With a network spanning rare diseases, oncology, cardiology, and beyond, OneMedNet delivers precision insights that redefine patient care and power the next wave of healthcare disruption.
OPIS provides full-service, 360° clinical trial support from study concept creation and protocol development to full project execution, study data handling and up to study closure, analysis, and reporting. We manage Phase I-IV, interventional, non-interventional and medical devices studies on an international level. In addition, OPIS also manages pre- and post-marketing clinical investigations for medical and diagnostic devices, nutraceutical, and food supplement studies.
OraBio, Inc. is a global leader in oral care solutions, specializing in products that support oral health for patients with chronic conditions. Our flagship Periovance Dry Mouth Gel provides effective relief for patients experiencing dry mouth due to medications, cancer treatments, aging, or lifestyle factors. Formulated to mimic natural saliva and enriched with key oral enzymes, Periovance Dry Mouth Gel is gentle on sensitive mouths, free from alcohol and menthol, and safe for frequent use throughout the day.
We’re a global cloud technology company providing secure, high‑performance infrastructure and modern applications that help organizations innovate, increase efficiency, and improve results. We created the world’s only autonomous database to better organize and protect data. Our cloud enables easy workload migration, resiliency, and sustainable growth. We support businesses, governments, and researchers, while fostering a diverse, growth‑oriented workplace.
Orion Pharma is a globally operating Nordic pharmaceutical company – a builder of well-being for over a hundred years. We develop, manufacture and market human & veterinary pharmaceuticals and active pharmaceutical ingredients. Our extensive portfolio consists of proprietary and generic medicines and consumer health products. Our pharmaceutical R&D core therapy areas are oncology and pain. Proprietary products developed by us are used to treat cancer, neurological diseases and respiratory diseases, among others. We employ around 4,000 professionals worldwide, dedicated to building well-being.
Parabilis Medicines is a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines that unlock disease targets long-considered undruggable through its proprietary Helicon™ platform. Parabilis’s lead candidate, zolucatetide, demonstrated the first inhibition of the key downstream node within the Wnt/β-catenin pathway, implicated in millions of cancers annually yet unaddressed by approved therapies. Parabilis is also advancing investigational degraders of ERG and allosteric ARON for prostate cancer, as well as other preclinical programs. Learn more: parabilismed.com
Paradigm Health is rebuilding the clinical research ecosystem by creating a platform that enables equitable access to trials for all patients, while enhancing trial efficiency and reducing the barriers to participation for healthcare providers. Incubated by ARCH Venture Partners and backed by leading healthcare and life sciences investors, Paradigm Health aims to break down barriers across the trial ecosystem through one seamless infrastructure implemented at healthcare provider organizations, bringing potentially life-saving therapies to patients faster.
Parexel is among the world’s largest clinical research organizations (CROs), providing the full range of Phase I to IV clinical development services to help life-saving treatments reach patients faster. Leveraging the breadth of our clinical, regulatory and therapeutic expertise, our team of more than 21,000 global professionals works in partnership with biopharmaceutical leaders, emerging innovators and sites to design and deliver clinical trials with patients in mind, increasing access and participation to make clinical research a care option for anyone, anywhere.
Partner Therapeutics is devoted to developing and commercializing cancer medicines and combination therapies that can make a meaningful difference in the lives of cancer patients. We are united in our passion for improving the treatment of cancer and our desire to make a meaningful contribution to outcomes.
At PathAI, we’re dedicated to improving patient outcomes with reliable AI-Powered technology and meaningful collaboration with biopharma, laboratories, and clinicians — aiming to provide patients with access to accurate diagnoses and effective treatments.
In March 2026, Patient Advocate Foundation and PAN Foundation announced a strategic merger, creating the most comprehensive U.S. nonprofit dedicated to helping patients navigate, access, and afford care. Operating as Patient Advocate Foundation, the combined organization unites 50 years of experience, expanded resources, and a stronger voice to directly support patients and advocate for policies that remove barriers to care. We’re uniting for patients.
Patient Empowerment Network (PEN) is a nonprofit covering all cancer types. PEN’s evidence-based programs provide patients living with cancer and their care partners with tools to feel activated and connected with resources that help overcome barriers in accessing care and bridging gaps among underrepresented communities.
For over 25 years, Paxman has led the way for chemotherapy side-effect management solutions, specifically for chemotherapy-induced alopecia and now peripheral neuropathy. The Paxman Scalp Cooling System is clinically proven to reduce hair loss and promote faster regrowth, offering patients a degree of control over their diagnosis. This treatment is now reimbursable via Category I CPT® codes. A cryocompression device to help prevent chemotherapy-induced nerve damage is currently undergoing regulatory approvals, with commercialization planned for later this year. Find us on booth 22031.
Penn Medicine’s Abramson Cancer Center (ACC) and the Ann B. Barshinger Cancer Institute are dedicated to compassionate cancer care and advancing clinical research. Penn Medicine's Cancer Care System consists of 7 hospitals, 3 Proton Therapy centers, 19+ outpatient centers, across 3 states, PA, NJ and DE. Stop by our booth to learn about job opportunities and meet our experts.
Penn State Health is an integrated academic health system that serves patients and communities across 15 counties in central Pennsylvania. Our mission is to improve health through patient care, research, education and community outreach. The system includes multiple hospitals and is uniquely positioned to turn new discoveries into patient breakthroughs by uniting its academic medical center with community hospitals.
The Pennsylvania Society of Oncology and Hematology is an organization of physicians and health care professionals dedicated to advancing quality hematologic and oncologic care through education, advocacy, networking, and leadership.
At Perceptive Imaging, we empower pharmaceutical, biotech, and clinical research organizations to rapidly discover and advance life-changing medicines by delivering unmatched scientific and technological expertise, global operational experience, and end-to-end solutions that ensure confident R&D decision-making.
PharmaEssentia Corporation (TWSE: 6446), headquartered in Taiwan, with U.S. subsidiaries in Burlington and Bedford, MA, is a rapidly growing and fully integrated biopharmaceutical innovator. The company aims to deliver effective new biologics for challenging diseases in the areas of hematology and oncology, with one approved product and a diversifying pipeline. Founded in 2003, the company is now expanding its global presence with operations in the U.S., Japan, China and Korea. Visit our website to learn more.
Phesi's patient-centric clinical data science solutions deliver smarter oncology trials and faster cures. We use our AI-powered Trial Accelerator™ platform with global data from 375 million patients, 195 countries and 4,000 indications to create Digital Patient Profiles and our unique Patient Access Score to assess investigator potential. We deliver actionable insights with unrivalled precision to enable you to optimize protocol design, improve enrollment and reduce patient burden and cycle times. We can help you revolutionize clinical development with Digital Twins and External Control Arms.
Pickles Group is a national non-profit organization that provides free peer-to-peer support and resources to kids and teens impacted by their parent's cancer. Pickles Group programming is focused on providing kids and families with honest information about cancer, coping skills, and peer connection. Pickles Group offers a free Family Support Kit, How to Talk to Kids About Cancer webinars, Clinician webinars, and 2 virtual curriculum-based programs, in addition to in-person family gatherings for our Chicago-based families.
Pillar is a global provider of NGS kitted solutions designed to deliver high analytical performance and operational efficiency for cancer testing. Powered by proprietary SLIMamp® and PiVAT® technologies, Pillar enables localized testing to expand access to complex molecular diagnostics worldwide. The company offers a growing portfolio of IVD and RUO NGS kits targeting tumor profiling, biomarker analysis, and molecular research and monitoring applications. Pillar’s solutions are built to provide laboratories with reliable, reproducible results while improving workflow efficiency.
Portamedic is the largest nationwide mobile phlebotomy provider. We complete in home services in all 50 states and Puerto Rico. With over 100 branch offices and 4,000 mobile phlebotomists we have the skill and expertise to complete mobile blood draws anywhere and anytime. In 2025 we completed over 2 million mobile blood draws.
Precigen (Nasdaq: PGEN) is a biopharmaceutical company specializing in the advancement of innovative precision medicines to address difficult-to-treat diseases with high unmet patient need. Precigen is dedicated to advancing scientific breakthroughs from proof-of-concept through commercialization. With a strong commitment to innovation, Precigen is developing a robust pipeline of differentiated therapies across its core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases.
Premier Research International LLC (Premier) is a leading global clinical research organization (CRO) and consulting partner with expertise in driving an efficient and effective path to market for the life sciences industry. Built with the needs of biotech in mind, our integrated approach helps life science innovators turn breakthrough science into life-changing drugs, devices, and diagnostics by addressing trial complexity, overcoming development hurdles, and demonstrating product value.
Community oncologists are hard to reach, but they are a critical part of biopharma’s commercial and clinical strategy. Pharmaceutical companies partner with Primum to understand and effectively engage with our national community of oncologists. Oncologists join our community because Primum is the only place where they can confidentially connect with industry-leading experts on specific patient cases at point-of-care.
Project PINK BLUE is an African leading cancer organisation that is engaged in cancer awareness, patient advocacy, treatment support, oncology education, and cancer research. In 2015, we launched Nigeria’s first Patient Navigation Programme (PNP) with support from Union for International Cancer Control (UICC) & Pfizer Oncology. We currently host the largest cancer support group in Nigeria. Project PINK BLUE is changing the way Africans think about cancer every single day! We believe that geography should not determine whether cancer patients live or die.
PSI CRO is a privately-owned, full-service clinical research organization (CRO) operating globally. PSI’s global reach supports clinical trials across multiple countries and continents and specializes in the planning and execution of global pivotal registration clinical trials. With an exceptionally high repeat and referral business rate combined with minimal staff turnover, PSI is committed to being the best CRO in the world as measured by its employees, customers, investigators, and vendors.
Puma Biotechnology develops and commercializes innovative products to enhance cancer care. We in-licensed global development and commercialization rights to neratinib in 2011 and alisertib, an aurora kinase A inhibitor, in 2022. We are pursuing development of alisertib initially in small cell lung cancer and HER2 negative, HR-positive metastatic breast cancer. In February 2024, we initiated ALISCA™-Lung 1 (PUMA-ALI-4201) and in November 2024, we initiated ALISCA™-Breast1 (PUMA-ALI-1201). Enrollment was completed in March 2026 and the study remains ongoing.
QPS is a GLP/GCP‑compliant CRO providing discovery, preclinical, and clinical drug development services. Known for quality, technical expertise, flexibility, and turnkey labs, QPS delivers value for clients and patients. Founded in 1995, it has grown to 1,100+ employees across the US, Europe, India, and Asia, with strengths in Neuropharmacology, DMPK, Toxicology, Bioanalysis, Translational Medicine, and Clinical Development.
QuantHealth is the leader in AI-driven clinical trial simulations, helping life sciences design faster, more successful trials using real-world data and predictive modeling. With the industry’s most advanced clinical trial simulations portfolio — 600+ trial simulations across 30 diseases with up to 90% prediction accuracy — and the category’s largest real-world data set, QuantHealth solutions simulate trials at scale, optimize protocols, reduce risk, and accelerate timelines. The company is a trusted partner to twelve of the top 20 global pharmaceutical companies.
Quibim is a company leading at the forefront of imaging biomarkers research in life sciences, pioneering the development of advanced algorithms that transform imaging data into actionable predictions in oncology, immunology, and neurology. The company was founded with the ambition to leverage imaging as a catalyst for precision medicine, improving clinical outcomes for patients and redefining medical treatment and monitoring. Quibim utilizes MRI, CT, and PET imaging technologies to develop regulatory-cleared medical devices, integrating seamlessly into global healthcare workflows.
Qure.ai is a global health tech company that harnesses the power of artificial intelligence to advance enhance early clinical diagnosis and seamless care coordination across lung health, oncology. With 26 FDA cleared findings and over 65 CE certifications, Qure.ai’s technologies are trusted by healthcare providers, governments, and global health organizations to strengthen diagnostic capacity and improve patient outcomes. The company also collaborates with leading pharmaceutical and life sciences partners to accelerate disease screening, research, and clinical development.
radiomics.bio is an AI-powered medical imaging & advanced statistics clinical research organisation, optimising the development of new oncology treatments. radiomics.bio supports biotech & pharma companies in all stages of clinical development offering services including disease characterization, dose impact quantification, response evaluation, image biomarker identification and outcome predictions.
For two decades, RadMD has been the trusted partner for imaging excellence in clinical research. As a global Imaging Contract Research Organization (iCRO), we provide end to end imaging solutions for Phase I–IV oncology and hematology trials. With a network of more than 300 radiologists and imaging specialists, we bring deep medical, scientific, and operational expertise to deliver high quality, compliant, and scalable image analysis, accelerating decision making and reducing risk across development. If you’re advancing a therapy where imaging endpoints matter, we’d welcome a conversation
Rakuten Medical, Inc. is a global biotechnology company developing and commercializing Alluminox® platform-based photoimmunotherapy, which has been shown to induce rapid and selective cell killing. Rakuten Medical’s photoimmunotherapy is currently investigational outside Japan. Rakuten Medical is committed to its mission to conquer cancer by developing its pioneering treatments as quickly as possible to as many patients as possible all over the world. The company has offices in 5 countries/regions, including the United States, where it is headquartered, Japan, Taiwan, Switzerland and India.
RayzeBio is a biotechnology company focused on improving outcomes for people with cancer by harnessing the power of targeted radioisotopes. With a focus on clinically validated solid tumor targets, RayzeBio is developing novel drug conjugates to deliver potent therapeutic radioisotopes such as Actinium-225, an alpha-emitter.
We provide human biospecimens for cancer research, including FFPE, fresh/frozen, matched sets, and clinical remnants for diagnostics, CROs, and biopharma. From annotated tumors to cfDNA with known variants and NGS‑ready material, we deliver fast, reliable, transparent sourcing so sample access never slows innovation.
Replimune Group Inc., headquartered in Woburn, MA was founded in 2015 with the mission to transform cancer treatment by pioneering the development of a novel portfolio of oncolytic immunotherapies. Replimune’s proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The RPx platform is designed to have a unique dual local and systemic activity consisting of direct selective virus-mediated killing of the tumor resulting in the release of tumor derived antigens and altering of the tumor
RepPrep.ai is a leading AI-driven sales enablement platform built specifically for the MedTech and life sciences industries. By combining commercial and Medicare claims data, CPT/ICD-10 insights, payer mix analysis, and proprietary physician datasets, RepPrep.ai equips medical sales representatives with customized pre-call plans, territory intelligence, and competitive insights in seconds. RepPrep.ai was designed to solve the biggest challenges facing today’s reps, limited access to accurate data, inconsistent preparation, and the increasing complexity of healthcare decision-making.
Research To Practice (RTP) is a medical education company based in Miami, Florida, specializing in physician and allied health professional education focused exclusively on oncology and hematology. Founded and led by medical oncologist Neil Love, MD, RTP has provided meaningful, relevant and unbiased educational perspectives for more than 30 years to meet the needs of oncology clinicians and positively impact the care of patients with cancer.
Resilience Care offers a remote therapeutic monitoring medical device (CE class IIa certified) designed for patients with cancer. This solution includes a monitoring platform that helps healthcare professionals better understand patients, proactively adjust treatments, and improve follow-up through PRO data collection. It also features a mobile application designed to support individuals in managing treatment-related side effects through tailored educational resources.
Resonant Clinical Solutions provides end‑to‑end clinical trial and diagnostic services, combining life sciences logistics expertise with agile collaboration and personalized support. We manage biorepositories, custom kitting, global logistics, and equipment services with precision and compliance. Through strategic service centers and a global network, we streamline complex workflows and help teams advance science. Kitting by Therapak Biorepository by EPL Archives Equipment & Ancillaries by MESM
Founded in 1991, the Colorado Oncology Society (COS) is the largest oncology professional organization in the state. COS comprises a powerful community of oncologists, nurse practitioners, physician assistants, pharmacists, and other multidisciplinary care providers involved in the treatment of patients with cancer.
Founded in 1898 and operating from a 28-acre campus on the Buffalo Niagara Medical Campus near downtown Buffalo, New York, Roswell Park today remains the state's only comprehensive cancer center designated by the National Cancer Institute (NCI) outside of New York City. In the past year, Roswell Park teams cared for more than 52,000 patients. Roswell Park helps set international standards in cancer care through its role as a founding member of the National Comprehensive Cancer Network, and consistently earns patient-satisfaction scores that are among the highest in the country.
As New Jersey’s only National Cancer Institute-designated Comprehensive Cancer Center, Rutgers Cancer Institute together with RWJBarnabas Health offer innovative cancer treatment options including CAR-T cell therapy, stem cell transplant, proton therapy, clinical trials, precision medicine and immunotherapy. More than 230 faculty members in interdisciplinary programs supported by peer-reviewed grants, focus on basic, clinical, translational and population research that drives outstanding scientific contributions towards reducing cancer incidence and improving patient outcomes.
At SAGA Diagnostics, our mission is to intercept cancer as early as possible, for every patient. We are a personalized cancer diagnostics and disease monitoring company focused on molecular analyses of circulating tumor DNA (ctDNA), thereby enabling precision cancer medicine, providing more accurate treatment monitoring, and improving patient outcomes. SAGA’s proprietary MRD testing technology helps patients, oncologists, and drug developers to detect pre- and post-curative intent residual disease, treatment response and disease recurrence with unprecedented sensitivity and specificity.
Sampled is an integrated laboratory and biorepository service provider with industry-leading storage, sample management, multiomics, cellular services, and custom clinical kitting. Sampled operates facilities in the US and UK and is CAP accredited and CLIA licensed. Sampled is committed to providing the highest quality sample storage, processing, and analysis services that enable researchers to make new discoveries and advance human health.
The San Antonio Breast Cancer Symposium is designed to provide state-of-the-art information on the experimental biology, etiology, prevention, diagnosis, and therapy of breast cancer and premalignant breast disease to an international audience of academic and private physicians and researchers. The scientific program consists of formal lectures by experts in clinical, translational, and basic research.
SFA’s mission is to improve outcomes for people diagnosed with sarcoma to increase the number of survivors. We do this by funding and advancing research, educating and providing resources for people diagnosed with sarcoma, advocating on behalf of the community, bringing together the collective sarcoma voice, and growing awareness about the disease. As the largest and most visible sarcoma organization, SFA is the first line resource for all things sarcoma.
Scientist.com is a privately held San Diego-based company on a mission to make it faster and cheaper to discover new medicines. At its heart is an AI-powered marketplace that helps drug researchers use innovative technologies to rapidly translate their ideas into actionable data. Through Scientist.com, scientists communicate directly with research experts at over 4,000 global laboratories to design and execute complex research experiments. Visit scientist.com to learn more.
Scout proudly celebrates over 30 years of empowering clinical trials with people-first solutions and industry-leading tech. Operating in 100+ countries, we deliver face-to-face, virtual, and hybrid clinical meeting planning, patient payment, and travel and logistics support for top pharmaceutical and biotechnology companies. Learn more about our legacy at scoutclinical.com.
We partner with pharmaceutical and biotech companies, physicians and patients to advance the science of cancer treatments. Sarah Cannon Research Institute (SCRI) is a global leader in oncology research, conducting clinical trials in the community for more than 30 years. Our contributions to pivotal research have helped to advance the majority of new cancer therapies approved by the FDA today.
Engage with more than one million physicians globally on Sermo, a unique online community connecting doctors around the world to improve healthcare. Every day, thousands of physicians come to Sermo to democratize medical knowledge, crowdsource difficult patient cases, earn for their expertise through market research surveys, rate drugs to improve treatment decision-making, and even laugh at some great jokes. Join the community at sermo.com/join
Shengsheng International ("SSI") is a global supply chain and logistics company servicing the life science and biopharma industry. We specialize in providing professional and customized transport & supply chain solutions for clinical trials, commercial medical products, API and drug substances, biological samples and kitting, as well as live animals for research and developments.
SITC is the leading member-driven society dedicated to improving cancer patient outcomes by advancing immunotherapy science and application. SITC is a 501(c)(3) not-for-profit professional society of research and physician-scientists, clinicians, patients, patient advocates, government representatives, and industry leaders dedicated to improving cancer patient outcomes by advancing the science and application of cancer immunotherapy. The Journal for ImmunoTherapy of Cancer (JITC) is an open access, peer-reviewed journal and the official journal of SITC.
Society for Integrative Oncology (SIO): SIO is at the forefront of evidence-based integrative oncology, developing rigorous clinical practice guidelines in collaboration with ASCO. They advance professional education and the global integration of safe, effective supportive therapies to improve the lives of those affected by cancer. Integrative Oncology (IO) Scholars Program: This NCI-funded, year-long training program from the University of Michigan empowers oncology professionals to evaluate and implement evidence-based complementary therapies. Through virtual sessions and clinical practicum
SOPHiA GENETICS (Nasdaq: SOPH) is a software company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It is the creator of the SOPHiA DDM™ Platform, a cloud-native platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The SOPHiA DDM™ Platform and related solutions, products and services are currently used by a broad network of hospital, laboratory, and biopharma institutions globally.
Founded in 1997, the South Carolina Oncology Society (SCOS) is the largest oncology professional organization in the state. SCOS comprises a powerful community of oncologists, nurse practitioners, physician assistants, pharmacists, and other multidisciplinary care providers involved in the treatment of patients with cancer.
Springer Nature advances discovery by serving the whole research community. All the research we publish is robust and in the best possible format to be discovered, accessed, used, re-used and shared. Springer Nature is home to brands including Springer, Nature Portfolio, BMC, and Scientific American. Visit our booth to learn about the benefits of publishing with us and to browse our latest titles on display.
Sumitomo Pharma America (SMPA) is a science‑based, technology‑driven biopharmaceutical company advancing therapeutic breakthroughs in oncology, urology, women’s health, rare disease, cell and gene therapy, and CNS. Formed through the consolidation of Sumitomo Pharma’s U.S. affiliates—including Sunovion, Myovant, Urovant, Enzyvant, and others—SMPA operates as part of Sumitomo Pharma.
Sun Pharma is a leading global pharmaceutical company, providing high-quality medicines trusted by patients. Every day, we help millions of Americans through our diverse portfolio of Innovative Medicines, Generics and Consumer Healthcare products. Our local manufacturing and distribution enables delivery of high-quality therapies that meet the highest regulatory standards.
Support for People with Oral and Head and Neck Cancer (SPOHNC), founded in 1991 by an oral cancer survivor, is a not-for-profit organization committed to improving the lives of patients, survivors and their families. SPOHNC provides resources, publications, and support to address the community's medical, emotional, and psychosocial challenges. With a focus on awareness and advocacy, SPOHNC connects individuals to vital information and a compassionate support network. Visit www.spohnc.org to learn more about the programs and resources offered.
SurvivingBreastCancer.org (SBC) is a national nonprofit dedicated to ensuring that no one faces breast cancer alone. Through education, community, and integrative oncology–inspired programs, SBC provides free resources, support groups, and wellness opportunities to empower those impacted by breast cancer to live fully and thrive. At SBC, we believe healing is more than medical treatment—it’s emotional, mental, and spiritual well-being. Our holistic approach bridges evidence-based education with whole-person support, creating a community where every individual feels seen, supported, and emp
SurvivorNet is the leading digital media health platform in the cancer space. You can see interviews with Nobel Prize winners, award winning journalists and many of the top specialists in cancer practicing in the country today as well as thousands of videos about cancer survivors and caregivers. Our audience is made up of people recently diagnosed with cancer, their caregivers and survivors who are looking for the latest news and information about cancer. Our platform exists to provide hope and information to help our community make better decisions about their care.
Susan G. Komen® is the world’s leading nonprofit breast cancer organization, working to save lives and end breast cancer forever. Komen has an unmatched, comprehensive 360-degree approach to fighting this disease across all fronts and supporting millions of people in the U.S. and in countries worldwide. We advocate for patients, drive research breakthroughs, improve access to high-quality care, offer direct patient support and empower people with trustworthy information.
Sutter Health is a leading healthcare system that provides high-quality, patient-centered care to communities in Northern California and other areas. With a network of hospitals, clinics, and physicians, Sutter's divisions offer a wide range of services and specialties to meet the diverse needs of its patients. Sutter's commitment to innovation and collaboration drives their success in delivering exceptional care and improving the health of their communities. To view current opportunities check us out at: https://jobs.sutterhealthclinicians.org/
Syneos Health® is a leading fully integrated biopharmaceutical solutions organization built to accelerate customer success. We translate unique clinical, medical affairs and commercial insights into outcomes to address modern market realities. Together we share insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients. We support a diverse, equitable and inclusive culture. To learn more about how we are Shortening the distance from lab to life®, visit syneoshealth.com.
As a contract research organization (CRO) specializing in oncology and precision medicine, TD2 Oncology collaborates with innovative biotech and pharmaceutical companies to expedite the delivery of treatments for rare cancers to patients. TD2 offers exclusive access to its Oncology Ecosystem, which includes services for clinical trial management, regulatory support, preclinical studies, and flow cytometry. This comprehensive support aims to maximize the success of your research.
TOPS strives to promote the highest professional standards of oncology in the state through member-driven educational programs, peer-to-peer networking opportunities, and collaboration with local organizations and industry trailblazers.
TerSera Therapeutics is a biopharmaceutical company with a focus in oncology and rare disease. We are building new cornerstones of care through our portfolio of unique therapeutics, amplifying their ability to deliver meaningful outcomes for patients.
The Texas Society of Clinical Oncology (TxSCO) represents the common interests of oncologists and hematologists treating cancer in Texas. We provide educational programs, networking opportunities, and robust advocacy support to help practices stay ahead of the shifting healthcare landscape and meet the challenges that directly impact how they care for their patients.
Founded in 1991, The Arizona Clinical Oncology Society (TACOS) is the largest oncology professional organization in the state. TACOS comprises a powerful community of oncologists, nurse practitioners, physician assistants, pharmacists, and other multidisciplinary care providers involved in the treatment of patients with cancer.
Founded in 2020, the Wyoming State Oncology Society (WSOS) is the largest oncology professional organization in the state. WSOS comprises a powerful community of oncologists, nurse practitioners, physician assistants, pharmacists, and other multidisciplinary care providers involved in the treatment of patients with cancer.
Xencor is a clinical-stage biopharmaceutical company advancing antibody therapeutics designed to deliver clinically differentiated activity for patients with cancer and autoimmune diseases. Leveraging our XmAb protein engineering platforms, we rapidly design, engineer and advance purpose-built drug candidates with novel mechanisms of action. Our oncology pipeline is concentrated on T-cell engaging bispecific antibodies, with lead investigational programs including XmAb819 (ENPP3 x CD3) for clear cell renal cell carcinoma and other high ENPP3 expressing tumor types and XmAb541 (CLDN6 x CD3).
Young Adult Survivors United (YASU) provides emotional, social, and financial support to young adults aged 18-45 when diagnosed with cancer, including support for their caregivers. Headquartered in Pittsburgh, PA, an in-person community of support is offered in Southwest PA while virtual support is offered to YAs and caregivers in the U.S. All services are free of charge.
Yourgene Health are an international molecular diagnostics business. Yourgene's DPYD genotyping PCR assay supports safer chemotherapy regimes, by identifying patients at risk of severe fluoropyrimidine toxicity. Early detection of DPD deficiency before starting 5-FU treatment enables clinicians to adjust chemotherapy dosing and avoid serious, potentially life-threatening adverse reactions. Powered by Ranger® Technology, our portfolio of automated DNA size selection instruments delivers high-precision size selection and dynamic target enrichment across a wide range of clinical applications.
Yunu is redefining how imaging powers clinical research. The company’s intelligent, end-to-end workflow platform streamlines every stage of imaging-based trials—from image capture and reader assignment to adjudication and data export—ensuring scientific integrity and operational efficiency. Trusted by life sciences, pharmaceutical, cancer centers, and research organizations worldwide, Yunu empowers teams to manage complex imaging studies with clarity, confidence, and speed.
Zentalis is a clinical oncology innovator developing a treatment approach for ovarian cancer and multiple tumor types. Leveraging therapeutics development and biomarker expertise, Zentalis is advancing monotherapy and combination studies of its first-in-class WEE1 inhibitor, azenosertib. Focused on translating WEE1 science into clinical practice, we aim to equip physicians with a targeted, non-chemo, orally available medicine that enhances treatment experience, choice, and outcomes. Our mission: to unburden cancer patients with more convenience and care.